Production and maintenance of stem cells
Patent Information
- Application Number
- JP2024081065
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2008-12-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods have struggled to maintain and induce pluripotency in pluripotent stem cells, particularly in mammals other than mice, such as rats, and induced pluripotent stem cells, due to differences in signaling requirements and culture conditions, leading to instability and rapid differentiation.
The use of ALK5 inhibitors in combination with MAPK inhibitors, such as MEK or Erk inhibitors, or FGF signaling pathway inhibitors, along with GSK3β inhibitors and leukemia inhibitory factor (LIF), creates a culture environment that supports stable pluripotency and self-renewal of pluripotent cells, including rat and human cells, by inhibiting the TGFβ/activin and MAPK pathways.
This approach allows for the maintenance of pluripotency over multiple cell divisions and passages, enabling cells to retain their pluripotent characteristics, differentiate into all three germ layers, and contribute to chimeric offspring when reintroduced into blastocysts, resembling mouse embryonic stem cell-like states.
Smart Images

Figure 00000067_0000 
Figure 00000067_0001 
Figure 00000067_0002
Abstract
Description
[Background technology]
[0001] 2. Background of the Invention Embryonic stem cells (ESCs) have been established from mice since 1981, but attempts to obtain their counterparts from various other mammals, including rats, have been unsuccessful. Recently, pluripotent stem cells have been derived from the postimplantation egg cylinder stage epiblast of mice and rats (Brons et al., Nature 448, 191-195 (2007);Tesar et al., Nature 448, 196-199 (2007)). These novel stem cells have been named epiblast stem cells (EpiSCs). EpiSCs appear to closely match human embryonic stem cells (hESCs) in colony morphology and culture / signaling requirements to maintain diversity, but display a series of striking differences in phenotype and signaling responses from mouse embryonic stem cells (mESCs).
[0002] Leukemia inhibitory factor (LIF) is essential to maintain pluripotency of mESCs in the presence of serum via the JAK-STAT3 pathway (Niwa et al., Genes Dev 12, 2048-2060 (1998)). However, in serum-free medium, BMP4 is also required along with LIF to sustain mESC self-renewal by inducing inhibitor of differentiation (Id) protein expression (Ying et al., Cell 115, 281-292 (2003)) and inhibiting ERK activation (Qi et al., Proc Natl Acad Sci USA 101, 6027-6032 (2005)). In contrast to mESCs, LIF cannot support EpiSCs / hESCs, which typically require basic fibroblast growth factor (bFGF) / activin A for long-term self-renewal. Undifferentiated hESCs exhibit high levels of basal ERK activity due to bFGF signaling (Dvorak et al., Stem Cells 23, 1200-1211 (2005)). BMP4 also does not support EpiSC / hESC self-renewal, but rather induces EpiSC / hESCs to differentiate into trophoblast or primitive endoderm (Brons et al., Nature 448, 191-195 (2007);Tesar et al., Nature 448, 196-199 (2007);Xu et al., Nat Biotechnol 20, 1261-1264 (2002)). Not only bFGF but also Activin A / Nodal signaling has been shown to support the undifferentiated state of hESCs / EpiSCs (Brons et al., Nature 448, 191-195 (2007); Sato et al., Dev Biol 260, 404-413 (2003); Tesar et al., Nature 448, 196-199 (2007)), but it is not essential for mESCs.These results strongly support the view that EpiSCs and hESCs are essentially similar and raise the attractive hypothesis that mESCs and EpiSCs / hESCs represent two distinct pluripotent states: an mESC-like state corresponding to the preimplantation inner cell mass (ICM) and an EpiSC-like state corresponding to the subsequent epiblast cells, respectively.
[0003] mESCs can usually be derived from certain mouse strains using feeder-layer-based cell culture conditions (Martin, GR, Proc Natl Acad Sci USA 78, 7634-7638 (1981)), but it has proven difficult to derive authentic ES cells from rats under similar conditions. Although the establishment of rat ESC-like cells has been reported (Demers et al., Cloning Stem Cells 9, 512-522 (2007); Ruhnke et al., Stem Cells 21, 428-436 (2003); Schulze et al., Methods Mol Biol 329, 45-58 (2006); Ueda et al., PLoS ONE 3, e2800 (2008)), these cells could not be stably maintained or lacked true in vivo pluripotency (e.g., inability to form teratomas or little / no contribution to chimerism). Similarly, (in vitro) pluripotent rat EpiSCs have been derived, but both rat and mouse EpiSCs show little or no ability to reintegrate into preimplantation embryos and contribute to chimeras (Brons et al., Nature 448, 191-195 (2007); Tesar et al., Nature 448, 196-199 (2007)).
[0004] Recently, induced pluripotent stem cells (iPSCs), which are generated from both mouse and human somatic cells by defined gene transduction, have attracted tremendous interest (Dimos et al., Science 321, 1218-1221 (2008); Han, J. and Sidhu, KS Curr Stem Cell Res Ther 3, 66-74 (2008); Takahashi et al., Cell 131, 861-872 (2007); Takahashi, K. and Yamanaka, S., Cell 126, 663-676 (2006); Yu et al., Science 318, 1917-1920 (2007)). Summary of the Invention
[0005] BRIEF SUMMARY OF THE INVETION The present invention provides a method for culturing pluripotent cells for at least one cell division. In some embodiments, the method comprises culturing a sufficient amount of pluripotent cells to allow at least one cell division while maintaining the pluripotency of the cells. a. an ALK5 inhibitor (or other TGFβ / activin pathway inhibitor), and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor; and c. Adequate nutrients for an adequate period of time The method includes culturing the pluripotent animal cells in the presence of
[0006] In some embodiments, the culturing step further comprises culturing the cells in the presence of an amount of a GSK3β inhibitor. In some embodiments, the GSK3β inhibitor is CHIR99021.
[0007] In some embodiments, the second compound is a MEK inhibitor. In some embodiments, the MEK inhibitor is PD0325901.
[0008] In some embodiments, the second compound is an Erk inhibitor.
[0009] In some embodiments, the culturing step is carried out in the additional presence of Leukemia inhibiting factor (LIF).
[0010] In some embodiments, the ALK5 inhibitor is A-83-01. In some embodiments, the ALK5 inhibitor is SB431542.
[0011] In some embodiments, the pluripotent cells are cultured for at least five cell doublings while maintaining the pluripotency of the cells.
[0012] In some embodiments, the method further comprises introducing a heterologous nucleic acid into the pluripotent cell and culturing the resulting cell to allow at least one additional cell division while maintaining pluripotency. In some embodiments, the heterologous nucleic acid is introduced into the animal cell, then pluripotency is induced, and then the cell is subjected to a culturing step.
[0013] In some embodiments, the cell is a rat cell or a human cell, hi some embodiments, the cell is a primate, ovine, bovine, feline, canine, or porcine cell.
[0014] In some embodiments, the pluripotent cells are embryonic stem cells. In some embodiments, the pluripotent cells are induced pluripotent stem cells.
[0015] In some embodiments, the cells are non-human animal cells and the method further comprises introducing the pluripotent cells into a blastocyst derived from the same species of animal as the cells, and introducing the blastocyst into a uterus of an animal of the same species, hi some embodiments, the method comprises selecting chimeric progeny of the animal based on the presence of nucleic acid derived from the pluripotent cells.
[0016] The present invention also provides cultures of pluripotent mammalian cells. In some embodiments, the cultures are cultured in sufficient amounts to allow at least one cell division while maintaining the pluripotency of the cells. a. an ALK5 inhibitor (or other TGFβ / activin pathway inhibitor), and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. Includes.
[0017] In some embodiments, the culture further comprises LIF.
[0018] In some embodiments, the culture further comprises an amount of a GSK3β inhibitor. In some embodiments, the GSK3β inhibitor is CHIR99021.
[0019] In some embodiments, the second compound is a MEK inhibitor. In some embodiments, the MEK inhibitor is PD0325901.
[0020] In some embodiments, the second compound is an Erk inhibitor. In some embodiments, the ALK5 inhibitor is A-83-01. In some embodiments, the ALK5 inhibitor is SB431542.
[0021] In some embodiments, the cell is a rat cell or a human cell. In some embodiments, the cell is a primate, ovine, bovine, feline, canine, or porcine cell. In some embodiments, the cell is an induced pluripotent stem cell or an embryonic stem cell.
[0022] The present invention also provides a cell culture medium. In some embodiments, the medium contains a sufficient amount of pluripotent cells to allow at least one cell division while maintaining the pluripotency of the cells when cultured in the medium. a. an ALK5 inhibitor (or other TGFβ / activin pathway inhibitor), and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. Includes.
[0023] In some embodiments, the medium further comprises LIF.
[0024] In some embodiments, the medium further comprises an amount of a GSK3β inhibitor. In some embodiments, the GSK3β inhibitor is CHIR99021.
[0025] In some embodiments, the second compound is a MEK inhibitor. In some embodiments, the MEK inhibitor is PD0325901.
[0026] In some embodiments, the second compound is an Erk inhibitor. In some embodiments, the ALK5 inhibitor is A-83-01. In some embodiments, the ALK5 inhibitor is SB431542.
[0027] In some embodiments, the medium is in a prepackaged sealed container, hi some embodiments, the medium comprises DMEM or other medium adapted for growing human, rat, mouse or other animal cells.
[0028] The present invention also provides an isolated pluripotent animal cell that replicates and maintains pluripotency in the presence of leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP), or under the inhibition of TGFβ and activin signaling pathway, under the inhibition of MAPK signaling pathway, and optionally under the inhibition of FGF pathway. In some embodiments, the isolated pluripotent animal cell is not a mouse embryonic stem cell (mESC). In some embodiments, the cell is a human cell. In some embodiments, the cell is a human embryonic stem cell. In some embodiments, the cell is a human iPS cell. In some embodiments, the cell is a rat cell. In some embodiments, the cell is a rat embryonic stem cell. In some embodiments, the cell is a rat iPS cell. In some embodiments, the cell maintains pluripotency under the inhibition of ALK5 and MEK. In some embodiments, the cell comprises a heterologous expression cassette (e.g., but not limited to, an expression cassette encoding a selectable or detectable marker (e.g., alkaline phosphatase)).
[0029] The isolated pluripotent cells of the present invention express higher levels of E-cadherin compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells.For example, the isolated pluripotent animal cells express 2-fold higher levels of E-cadherin compared to conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells.In some embodiments, the isolated pluripotent animal cells express higher levels of markers, including Gbx2, Dppa3, Klf4, and Rexl compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells.
[0030] In some embodiments, the isolated pluripotent cell of the present invention is cultured in the presence of ALK5 inhibitor and in the presence of a second compound selected from MEK inhibitor, Erk inhibitor, p38 inhibitor, and FGF receptor inhibitor.In some embodiments, the isolated pluripotent cell of the present invention is obtained or can be obtained by culturing cells in the presence of ALK5 inhibitor and in the presence of a second compound selected from one or more of MEK inhibitor, Erk inhibitor, p38 inhibitor, and FGF receptor inhibitor.For example, the isolated pluripotent cell of the present invention is obtained or can be obtained by culturing conventionally cultured hESC, EpiSC, rat ESC, or primate ESC.
[0031] The present invention also provides methods for enhancing the pluripotency of a partially pluripotent mammalian cell to a more fully pluripotent cell. In some embodiments, the methods include: (a) contacting a defective pluripotent cell with an epigenetic modifier selected from a histone deacetylase inhibitor, an inhibitor of histone H3K4 demethylation, or an activator of H3K4 methylation; (b) after step (a), culturing the cells with two or more of: (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, in the absence of epigenetic modifiers, thereby generating cells that are more fully pluripotent as compared to said incompletely pluripotent mammalian cells. Includes.
[0032] In some embodiments, the method further comprises: (c) culturing the defective pluripotent mammalian cells after step (b) with (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, and (iv) a GSK3 inhibitor. Includes.
[0033] In some embodiments, the culturing steps (a) and / or (b) and / or (c) further comprise culturing the defective pluripotent mammalian cells in the presence of leukemia inhibitory factor (LIF).
[0034] In some embodiments, the defective pluripotent cells are epiblast stem cells.
[0035] In some embodiments, a partially pluripotent cell does not express at least one marker selected from the group consisting of Oct4, Nanog, SSEA-1, and REX-1, and a more fully pluripotent cell expresses one or more or all of those markers.
[0036] In some embodiments, the partially pluripotent cells do not express ALP-1 and the more fully pluripotent cells express ALP-1.
[0037] In some embodiments, the epigenetic modifier is valproic acid or parnate. [Claim 1001] 1. A method of culturing pluripotent cells for at least one cell division, comprising: A sufficient amount of the cells was added to maintain pluripotency and to allow at least one cell division. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor; and c. Adequate nutrients for an adequate period of time Culturing the pluripotent animal cells in the presence of The method comprising: [Claim 1002] The method of claim 1001, wherein the culturing step further comprises culturing the cells in the presence of an amount of a GSK3β inhibitor. [Claim 1003] The method of claim 1002, wherein the GSK3β inhibitor is CHIR99021. [Claim 1004] The method of claim 1001, wherein the culturing step further comprises culturing the cells in the presence of an amount of leukemia inhibitory factor (LIF). [Claim 1005] The method of claim 1001, wherein the second compound is a MEK inhibitor. [Claim 1006] The method of claim 1005, wherein the MEK inhibitor is PD0325901. [Claim 1007] The method of claim 1001, wherein the second compound is an Erk inhibitor. [Claim 1008] The method of claim 1001, wherein the culturing step is performed in the presence of additional LIF. [Claim 1009] The method of claim 1001, wherein the ALK5 inhibitor is A-83-01. [Claim 1010] The method of claim 1001, wherein the ALK5 inhibitor is SB431542. [Claim 1011] The method of claim 1001, wherein the pluripotent cells are cultured for at least five cell divisions while maintaining the pluripotency of the cells. [Claim 1012] The method of claim 1001, further comprising the step of introducing a heterologous nucleic acid into the pluripotent cell and culturing the resulting cell to allow at least one additional cell division while maintaining pluripotency. [Claim 1013] The method of claim 1012, wherein the heterologous nucleic acid is introduced into an animal cell, which then induces pluripotency, and which then is subjected to a culture step. [Claim 1014] The method of claim 1001, wherein the cell is a rat cell or a human cell. [Claim 1015] The method of claim 1001, wherein said cell is a primate, ovine, bovine, feline, canine, or porcine cell. [Claim 1016] The method of claim 1001, wherein the pluripotent cell is an embryonic stem cell. [Claim 1017] The method of claim 1001, wherein the pluripotent cells are induced pluripotent stem cells. [Claim 1018] The method of claim 1001, further comprising the steps of introducing the pluripotent cells into a blastocyst derived from the same animal species as the cells, and introducing the blastocyst into a uterus of an animal of the same species, wherein the cells are non-human animal cells. [Claim 1019] The method of claim 1018, wherein chimeric progeny of the animal is selected based on the presence of nucleic acid derived from the pluripotent cell. [Claim 1020] A sufficient amount of the cells was added to maintain pluripotency and to allow at least one cell division. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. A culture of pluripotent mammalian cells comprising: [Claim 1021] The culture of claim 1020, further comprising leukemia inhibitory factor (LIF). [Claim 1022] The culture of claim 1020, further comprising an amount of a GSK3β inhibitor. [Claim 1023] The culture of claim 1022, wherein the GSK3β inhibitor is CHIR99021. [Claim 1024] The culture of claim 1020, wherein the second compound is a MEK inhibitor. [Claim 1025] The culture of claim 1024, wherein the MEK inhibitor is PD0325901. [Claim 1026] The culture of claim 1020, wherein the second compound is an Erk inhibitor. [Claim 1027] The culture of claim 1020, wherein the ALK5 inhibitor is A-83-01. [Claim 1028] The culture of claim 1020, wherein the ALK5 inhibitor is SB431542. [Claim 1029] The culture of claim 1020, wherein the cells are human cells or rat cells. [Claim 1030] The culture of claim 1020, wherein the cells are embryonic stem cells. [Claim 1031] 1. A cell culture medium comprising: A sufficient amount of the pluripotent cell is added to the medium so that the pluripotent cell can undergo at least one cell division while maintaining the pluripotency of the cell when cultured in the medium. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. The cell culture medium comprising: [Claim 1032] The medium of claim 1031, further comprising leukemia inhibitory factor (LIF). [Claim 1033] The medium of claim 1031, further comprising an amount of a GSK3β inhibitor. [Claim 1034] The medium of claim 1033, wherein the GSK3β inhibitor is CHIR99021. [Claim 1035] The medium of claim 1031, wherein the second compound is a MEK inhibitor. [Claim 1036] The medium of claim 1035, wherein the MEK inhibitor is PD0325901. [Claim 1037] The medium of claim 1031, wherein the second compound is an Erk inhibitor. [Claim 1038] The medium of claim 1031, wherein the ALK5 inhibitor is A-83-01. [Claim 1039] The medium of claim 1031, wherein the ALK5 inhibitor is SB431542. [Claim 1040] The medium of claim 1031, wherein the medium is in a packaged, sealed container. [Claim 1041] (1) in the presence of leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP), or (2) under inhibition of the TGFβ and activin signaling pathways, under inhibition of the MAPK signaling pathway, and optionally under inhibition of the FGF pathway; 1. An isolated pluripotent animal cell which replicates and maintains pluripotency, comprising: However, the isolated pluripotent animal cell is not a mouse embryonic stem cell (mESC). [Claim 1042] The isolated cell of claim 1041, which is a human cell. [Claim 1043] The isolated cell of claim 1042, which is a human embryonic stem cell. [Claim 1044] The isolated cell of claim 1041, which is a rat cell. [Claim 1045] The isolated cell of claim 1044, which is a rat embryonic stem cell. [Claim 1046] The isolated cell of claim 1041, which maintains pluripotency under inhibition of ALK5 and MEK. [Claim 1047] The isolated pluripotent animal cell of claim 1041, which expresses higher levels of E-cadherin as compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells. [Claim 1048] The isolated pluripotent animal cell of claim 1047, which expresses a two-fold higher level of E-cadherin as compared to conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells. [Claim 1049] The isolated pluripotent animal cell of claim 1041, which expresses higher levels of markers including Gbx2, Dppa3, Klf4, and Rex1 compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells. [Claim 1050] a. ALK5 inhibitors; b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, a GSK3 inhibitor, and an FGF receptor inhibitor. The isolated cell of claim 1041, cultured in the presence of. [Claim 1051] 1. A method for enhancing the pluripotency of a partially pluripotent mammalian cell to a more fully pluripotent cell, comprising: (a) contacting a defective pluripotent cell with an epigenetic modifier selected from a histone deacetylase inhibitor, an inhibitor of histone H3K4 demethylation, or an activator of H3K4 methylation; (b) after step (a), culturing the cells with two or more of: (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, in the absence of epigenetic modifiers, thereby generating cells that are more fully pluripotent as compared to said incompletely pluripotent mammalian cells. The method comprising: [Claim 1052] (c) culturing the defective pluripotent mammalian cells after step (b) with (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, and (iv) a GSK3 inhibitor. The method of claim 1051, further comprising: [Claim 1053] The method of claim 1051 or 1052, wherein the culturing steps (a) and / or (b) and / or (c) further comprise culturing the defective pluripotent mammalian cells in the presence of leukemia inhibitory factor (LIF). [Claim 1054] The method of claim 1051, wherein the defective pluripotent cells are epiblast stem cells. [Claim 1055] The method of claim 1051, wherein the incompletely pluripotent cells do not express at least one marker selected from the group consisting of Oct4, Nanog, and REX-1, and the more fully pluripotent cells express one or more or all of said markers. [Claim 1056] The method of claim 1051, wherein the incompletely pluripotent cells do not express ALP-1 and the more fully pluripotent cells express ALP-1. [Claim 1057] The method of claim 1051, wherein the epigenetic modifier is valproic acid or parnate. [Brief description of the drawings]
[0038] [Figure 1A]Figure 1 shows that mESC-like riPSCs were generated from rat WB-F344 cells after retroviral transduction of Oct4, Sox2 and Klf4, and could be captured / maintained under a combination of LIF, 0.5 μM PD0325901, 0.5 μM A-83-01 and 3 μM CHIR99021. ESC-like colonies were observed 10 days after transduction (A), but could not be maintained under conventional mESC culture conditions (B). In the presence of 0.5 μM PD0325901 and 3 μM CHIR99021, riPSCs could be maintained in culture for a short period of time, but showed extensive spontaneous differentiation (C). The combination of 0.5 μM PD0325901, 3 μM CHIR99021, and 0.5 μM A-83-01 enabled riPSCs to self-renew long-term and homogeneously (D) and form mESC-like dome-shaped colonies in culture (E). Immunocytochemistry revealed that riPSCs expressed typical mESC markers, such as Oct4 (F), Sox2 (G), SSEA-1 (H, green), and Nanog (H, red). RT-PCR analysis of the four clonal riPSC lines confirmed the expression of endogenous typical pluripotency markers (I), whereas the virally transduced genes were mostly silenced. The Oct4 promoter of the riPSC clones showed a demethylation pattern that was distinct from that of the parental WB-F344 cells (J). [Figure 1B] FIG. 1B is a continuation of FIG. 1A. [Figure 1C] This is a figure showing a continuation of Figure 1B. [Figure 1D] This is a continuation of Figure 1C. [Figure 1E] This is a continuation of Figure 1D. [Figure 1F] This is a continuation of Figure 1E. [Figure 1G] This is a continuation of Figure 1F. [Figure 1H] This is a continuation of Figure 1G. [Figure 1I] This is a continuation of Figure 1H. [Figure 1J] This is a continuation of Figure 1I. [Figure 1K] This is a continuation of Figure 1J. [Diagram 2] riPSCs have pluripotent developmental potential in vitro and in vivo. Immunostaining showed that riPSCs could differentiate into endodermal (albumin and Pdx1) (A and B), neuroectodermal (βIII-tubulin, Tuj1) (C) and mesodermal (Brachyury) (D) derivatives in vitro. riPSCs could also form teratomas in SCID mice, which consisted of all three germ layers (E–H). riPSCs with a WB F344 background could also generate chimeric rats after injection into Brown-Norway rat blastocysts (I). Relative magnification: A–E (100×), F–H and J–Q (200×). [Figure 3A] Figure 3. Generation of novel "mESC-like" hiPSCs. IMR90 human fibroblasts were transduced with Oct4, Sox2, Nanog, and Lin28 by lentivirus. hiPSC colonies were observed 3 weeks after transduction (A) and picked up 4 weeks after transduction. They were stably maintained under a cocktail of hLIF, 0.5 μM PD0325901, 0.5 μM A-83-01, and 3 μM CHIR99021. The hiPSCs formed dome-shaped colonies resembling mESCs (B). Under such conditions, the hiPSCs were positive for ALP (C) and other typical pluripotency markers (D-I). RT-PCR analysis of four clonal hiPSC lines confirmed the expression of endogenous pluripotency genes (J), whereas the majority of the virally transduced genes were silenced. The Oct4 promoter in hiPSC clones showed a demethylation pattern similar to that in conventionally cultured human ES cells, but distinct from that in the parental IMR90 fibroblasts (K). Karyotype analysis of hiPSCs is shown (L). [Figure 3B] FIG. 3B is a continuation of FIG. 3A. [Figure 3C] This is a figure showing a continuation of Figure 3B. [Figure 3D] This is a figure showing a continuation of Figure 3C. [Figure 3E] This is a figure showing a continuation of Figure 3D. [Figure 3F] This is a continuation of Figure 3E. [Figure 3G] This is a continuation of Figure 3F. [Figure 3H] This is a continuation of Figure 3G. [Figure 3I] This is a figure showing a continuation of Figure 3H. [Figure 3J] This is a continuation of Figure 3I. [Figure 3K] This is a continuation of Figure 3J. [Figure 3L] This is a continuation of Figure 3K. [Figure 4] Immunostaining showed that hiPSCs could effectively differentiate into endodermal (albumin) (A), neuroectodermal (βIII-tubulin, Tuj1) (B) and mesodermal (Brachyury) (C) derivatives in vitro. After transplantation into SCID mice, hiPSCs could form teratomas, which consisted of all three germ layers, including neuroepithelial-like structures (ectoderm) (D), tubular-like structures (endoderm) (D) and cartilage-like structures (mesoderm) (E). Relative magnification: A (100×), B–E (200×). [Diagram 5] Effect of different small molecule combinations on maintaining pluripotency of riPSCs in culture. riPSCs were trypsinized to single cells, seeded at a density of 103 cells per well in 6-well plates, and treated with different inhibitor combinations. After 5 days, ALP staining was performed to visualize riPSC colonies (A). ALP-positive colonies were counted from 10 random 40× fields for each condition, and the relative colony numbers are summarized in B. [Figure 6]EpiSCs differentiate under mESC growth conditions and do not readily convert to an ICM / mESC-like state. (A) Mouse ESC R1 grew as compact dome-shaped colonies in conventional mESC growth medium supplemented with LIF, which showed positive ALP activity (top left). EpiSCs grew as large flattened colonies in conventional hESC culture medium supplemented with bFGF, which showed negative ALP activity (top right). EpiSCs differentiated in conventional mESC growth medium supplemented with LIF (bottom left). EpiSCs also differentiated in conventional mESC growth medium (m / MFGi) supplemented with LIF and 0.5 μM MEK inhibitor PD0325901, 0.1 μM FGFR inhibitor PD173074, and 3 μM GSK3 inhibitor CHIR99021 (bottom right). (B) Schematic of the generation of converted cells. EpiSCs were trypsinized to single cells and plated on feeder cells under mESC self-renewal conditions supplemented with the indicated chemical compounds for approximately 4 days to induce conversion, followed by an additional 4 days of selection. Cultures were then replated and further selected and expanded for another 2 weeks, during which stable clones were picked. (C) Inhibition of TGFβ signaling with the selective ALK4 / 5 / 7 inhibitor A-83-01 (0.5 μM) induced EpiSCs to form more compact dome-shaped colonies expressing ALP. (D) These colonies could be further stably expanded in mESC growth medium (mAMFGi) supplemented with LIF and 0.5 μM A-83-01, 0.5 μM PD0325901, 0.1 μM PD173074, and 3 μM CHIR99021. (E) The LSD inhibitor parnate induced EpiSCs to form more compact dome-shaped colonies expressing ALP. These colonies could be further stably grown under mMFGi or (F) mAMFGi conditions. Note the mESC-like dome-shaped colonies and positive ALP activity. Scale bar, 50 μm. [Figure 7A]EpiSCs are converted to an ICM / mESC-like state by treatment with parnate and inhibitors of ALK4 / 5 / 7, MEK, FGFR and GSK3. (A) Efficiency of chimerism generation from three types of compound-treated cells. [Figure 7B] EpiSCs are converted to an ICM / mESC-like state by treatment with parnate and inhibitors of ALK4 / 5 / 7, MEK, FGFR and GSK3. (B) Stable mESC-like cells converted from EpiSCs by parnate / mAMFGi conditions contributed to chimerism in adult mice after transplantation of aggregated embryos into pseudopregnant mice. Agouti coat color originated from parnate / mAMFGi cells. [Figure 7C] EpiSCs are converted to an ICM / mESC-like state by treatment with parnate and inhibitors of ALK4 / 5 / 7, MEK, FGFR and GSK3.(C) PCR genotyping for the presence of GFP integration in multiple adult tissues. [Figure 7D] EpiSCs are converted to an ICM / mESC-like state by treatment with parnate and inhibitors of ALK4 / 5 / 7, MEK, FGFR and GSK3.(D) E13.5 embryos were examined by fluorescence for contribution from GFP-labeled parnate / mAMFGi cells, and GFP-positive cells were observed in multiple tissues of the embryo (higher magnification is shown in Figure 10A). [Figure 7E] EpiSCs are converted to an ICM / mESC-like state by treatment with parnate and inhibitors of ALK4 / 5 / 7, MEK, FGFR and GSK3. (E) GFP / SSEA-1 double positive cells in the gonads were isolated by FACS and examined for germline markers by real-time PCR. The results demonstrated specific expression of germline markers Blimp1 and Stella in the germline lineage contributed by parnate / mAMFGi cells. Bars: ±STDV. [Figure 8A]Molecular characterization of transformed Parnate / mAMFGi cells. (A) Immunocytochemistry showed homogenous expression of pluripotency markers, Oct4 (green), Nanog (red), and SSEA-1 (red), in Parnate / mAMFGi cells. [Figure 8B] Molecular characterization of transformed Parnate / mAMFGi cells. (B) Expression of specific ICM marker genes (Rex-1, Pecam1, Dax1, Dppa5, Esrrb, Fgf4, and Fbxo15), germline competence-related marker genes (Stella and Stra8), and epiblast gene (fgf5) in mESCs, EpiSCs, and Parnate / mAMFGi cells was analyzed by semi-quantitative RT-PCR. GADPH was used as a control. [Figure 8C] Molecular characterization of transformed Parnate / mAMFGi cells. (C) Transcriptome analysis of mESC, EpiSC, and Parnate / mAMFGi cells showed that Parnate / mAMFGi cells are much more similar to mESC than to EpiSC. For all three cell types, two biological replicates were used. [Figure 8D] Molecular characterization of transformed Parnate / mAMFGi cells. (D) Methylation analysis of Stella and Fgf4 promoters by bisulfite genomic sequencing. Open and closed circles indicate unmethylated and methylated CpGs, respectively. [Figure 8E] Molecular characterization of transformed Parnate / mAMFGi cells. (E) ChIP-QPCR analysis of the indicated histone modifications at the stella locus in different cells. Genomic DNA was immunoprecipitated from feeder-free cultured EpiSCs, R1-mESCs, and Parnate / mAMFGi cells with the indicated antibodies, followed by Q-PCR analysis with primer sets specific for the endogenous genomic locus encoding Stella. The levels of histone modifications were expressed as a percentage of input. IgG was used as a no-antibody control. [Figure 9] Functional characterization of transformed Parnate / mAMFGi cells. (A) Parnate / mAMFGi cells have a similar growth rate to mESCs. R1-mESCs and Parnate / mAMFGi cells were passaged every 3 days and cell numbers were counted every 24 hours. (B) Parnate / mAMFGi cells can be effectively differentiated in vitro into cells of three germ layers, including characteristic neuronal cells (βIII-tubulin and MAP2ab positive), cardiomyocytes (cardiac troponin and MHC positive), and endoderm cells (Sox17 or albumin positive). Nuclei were stained with DAPI. (D) BMP4 has differential effects on induction of mesodermal marker (Brachyury), trophoblast marker (Cdx2), and primitive endoderm marker (Gata6) expression in EpiSCs, mESCs, and Parnate / mAMFGi cells. (E) Directed step-wise cardiomyocyte differentiation in monolayer and chemically defined conditions demonstrated that Parnate / mAMFGi cells have a differentiation response similar to R1-mESCs and distinct from EpiSCs. Cells were characterized by CT3 staining and beating phenotype. [Figure 10] Parnate / mAMFGi cells contributed efficiently to chimeric mice. (A) Tissues from chimeric embryos. GFP-positive cells originating from Parnate / mAMFGi cells were observed in the gonads, brain, heart, intestine, lung, and kidney. (B) GFP genotyping of chimeric adult mice. Five mice were randomly selected and analyzed for GFP integration in five different tissues, namely, heart, lung, liver, brain, and spleen, by genomic PCR. GFP integration was positively detected in all five tissues in two adult mice and in four tissues in three mice, confirming that Parnate / mAMFGi cells can contribute to three germ layers (mesoderm, endoderm, and ectoderm) in vivo. [Figure 11]Homogeneous expression of pluripotency markers in transformed Parnate / mAMFGi cells under feeder cell or feeder-free culture conditions. (A) Parnate / mAMFGi cells were labeled with GFP and grown on feeders. Immunostaining results showed homogeneous expression of GFP and pluripotency markers Oct4 (red), Nanog (red), and SSEA-1 (red). (B) Undifferentiated Oct4-positive colonies arose from single Parnate / mAMFGi cells as efficiently as from single OG2-ES cells. Colonies were grown for several passages under feeder-free and N2B27 chemically defined conditions after single-cell seeding. Scale bar, 50 μm. (C) In the absence of LIF, Parnate / mAMFGi cells differentiated and lost Oct4 expression. Parnate / mAMFGi cells were grown under feeder-free and N2B27 chemically defined conditions after single-cell seeding. Growth factor supplementation was indicated. [Figure 12] The expression of STELLA was detected in transformed parnate / mAMFGi cells and R1-mESC cells, but not in EpiSCs. Immunostaining results showed the expression of STELLA and DAPI. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0039] definition The term "pluripotent" or "pluripotency" refers to cells that have the capacity to give rise to progeny that can, under appropriate conditions, differentiate into cell types that collectively exhibit characteristics associated with cell lineages derived from all three germ layers (endoderm, mesoderm, and ectoderm). Pluripotent stem cells can contribute to many or all tissues of prenatal, postnatal, or adult animals. Standard tests accepted in the art can be used to establish the pluripotency of a cell population (e.g., ability to form teratomas in 8-12 week old SCID mice), but identification of various pluripotent stem cell characteristics can also be used to detect pluripotent cells. Cellular pluripotency is a continuum that spans from fully pluripotent cells, e.g., embryonic stem cells and iPSCs, that can form all cells of the embryo proper, to partially or incompletely pluripotent cells, that can form all cells of the three germ layers but may not exhibit all of the characteristics of fully pluripotent cells (e.g., germline transmission or ability to generate an entire organism). In certain embodiments, the pluripotency of cells is improved from poorly or incompletely pluripotent cells to more pluripotent cells, or in certain embodiments, to fully pluripotent cells.Pluripotency can be assessed, for example, by teratoma formation, germline transmission, and tetraploid embryo complementation.In some embodiments, the expression of pluripotency genes or pluripotency markers, discussed in a separate section herein, can be used to assess the pluripotency of cells.
[0040] "Pluripotent stem cell characteristics" refer to cellular characteristics that distinguish pluripotent stem cells from other cells. The ability to produce progeny that can differentiate under appropriate conditions into cell types that collectively exhibit characteristics associated with cell lineages derived from all three germ layers (endoderm, mesoderm, and ectoderm) is a pluripotent stem cell characteristic. The expression or non-expression of certain combinations of molecular markers is also a pluripotent stem cell characteristic. For example, human pluripotent stem cells express at least some (optionally all) of the following non-limiting list of markers: SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-49 / 6E, ALP, Sox2, E-cadherin, UTF-1, Oct4, Rex1, and Nanog. Cell morphology associated with pluripotent stem cells is also a pluripotent stem cell characteristic.
[0041] The term "library" is used according to its common usage in the art to refer to a collection of molecules, which may be organized and / or cataloged in a manner such that individual members can be identified. Libraries can include, but are not limited to, combinatorial chemical libraries, natural product libraries, and peptide libraries.
[0042] A "recombinant" polynucleotide is a polynucleotide that is not in its natural state. For example, the polynucleotide contains a nucleotide sequence that is not found in nature, or the polynucleotide is in a context other than that in which it is found in nature, e.g., free from nucleotide sequences that are typically adjacent to the polynucleotide in nature, or adjacent to (or contiguous with) nucleotide sequences that are not typically adjacent to the polynucleotide. For example, the sequence of interest can be cloned into a vector or otherwise recombined with one or more additional nucleic acids.
[0043] "Expression cassette" refers to a polynucleotide comprising a promoter or other regulatory sequence operably linked to a protein-encoding sequence.
[0044] The terms "promoter" and "expression control sequence" are used herein to refer to a set of nucleic acid control sequences that direct the transcription of a nucleic acid. As used herein, a promoter includes essential nucleic acid sequences near the transcription start site, such as a TATA element in the case of a polymerase II type promoter. A promoter may also include distal enhancer or repressor elements, which may be located as far away as several thousand base pairs from the transcription start site. Promoters include constitutive and inducible promoters. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to an operable linkage between a nucleic acid expression control sequence (e.g., a promoter, or a set of transcription factor binding sites) and a second nucleic acid sequence, where the expression control sequence directs the transcription of the nucleic acid corresponding to the second sequence.
[0045] As used herein, a "heterologous sequence" or "heterologous nucleic acid" is derived from a source that is foreign to the particular host cell, or, if derived from the same source, is modified from its original form. Thus, a heterologous expression cassette in a cell is an expression cassette that is not endogenous to the particular host cell, for example, by being linked to a nucleotide sequence in an expression vector rather than chromosomal DNA, by being linked to a heterologous promoter, by being linked to a reporter gene, etc.
[0046] The term "agent" or "test compound" refers to any compound useful in the screening assays described herein. The agent can be, for example, an organic compound, a polypeptide (e.g., a peptide or an antibody), a nucleic acid (e.g., double-stranded or single-stranded DNA, RNA, oligonucleotides, antisense RNA, small inhibitory RNA, microRNA, ribozymes, etc.), an oligosaccharide, a lipid, etc. Typically, the agent used in the present screening method has a molecular weight of less than 10,000 daltons, e.g., less than 8000, 6000, 4000, 2000 daltons, e.g., 50-1500, 500-1500, 200-2000, 500-5000 daltons. The test compound can be in the form of a library of test compounds that provides a sufficient breadth of diversity, e.g., a combinatorial library or a randomized library. The test compound may be linked to a fusion partner, such as a targeting compound, a rescue compound, a dimerization compound, a stabilizing compound, an addressable compound, and other functional moieties. Typically, novel chemical entities with useful properties are created by identifying a test compound (called a "lead compound") that has some desirable property or activity (e.g., the ability to induce pluripotency under certain conditions as described herein), creating mutants of the lead compound, and evaluating the properties and activities of the mutant compounds. Often, high throughput screening (HTS) methods are used for such analyses.
[0047] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to deoxyribonucleotides or ribonucleotides and polymers thereof in single- or double-stranded form. The terms encompass synthetic, natural, and non-natural nucleic acids that contain known nucleotide analogs or modified backbone residues or modified backbone linkages that have similar binding properties and are metabolized in a manner similar to the reference nucleic acid. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide nucleic acids (PNAs), and the like.
[0048] Unless otherwise indicated, a particular nucleic acid sequence encompasses not only the sequence specified, but also its conservatively modified variants (e.g., degenerate codon substitutions) and complementary sequences.Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is replaced with mixed base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0049] The terms "inhibitor", "activator" and "modulator" of expression or activity are used to refer to inhibitory, activating or modulating molecules, such as ligands, agonists, antagonists, and homologs and mimetics thereof, identified using in vitro and in vivo assays for expression or activity of a described target protein (or a polynucleotide encoding same), respectively. The term "modulator" encompasses inhibitors and activators. Inhibitors are agents, such as antagonists, that inhibit, bind, partially or completely block stimulation or protease inhibitor activity, reduce, prevent, delay activation, inactivate, desensitize, or downregulate the activity of a described target protein. Activators are agents, e.g., agonists, that induce or activate, bind, stimulate, increase, open, activate, facilitate, enhance, sensitize, or upregulate the activity of the described target protein (or the polynucleotide encoding it), for example, the expression of the described target protein. Modulators include natural and synthetic ligands, antagonists and agonists (e.g., small chemical molecules, antibodies, etc. that function as agonists or antagonists). Such assays for inhibitors and activators include, for example, applying a putative modulator compound to cells expressing the described target protein and then determining the functional effect on the described target protein activity, as described above. Samples or assays containing the described target protein treated with a potential activator, inhibitor, or modulator are compared to control samples that do not contain the inhibitor, activator, or modulator to determine the extent of the effect. Control samples (untreated with modulators) are assigned a relative activity value of 100%. Inhibition of the described target protein is achieved when the activity value compared to the control is about 80%, optionally 50% or 25, 10%, 5% or 1%.Activation of the described target protein is achieved when the activity value is 110%, optionally 150%, optionally 200, 300%, 400%, 500%, or 1000-3000% or more compared to the control.
[0050] "Oct polypeptide" refers to any naturally occurring member of the Octamer transcription factor family, or a variant thereof that maintains a similar transcription factor activity (within at least 50%, 80%, or 90% activity) compared to the closest related naturally occurring family member, or a polypeptide that contains at least the DNA binding domain of a naturally occurring family member and may further contain a transcription activation domain. Exemplary Oct polypeptides include Oct-1, Oct-2, Oct-3 / 4, Oct-6, Oct-7, Oct-8, Oct-9, and Oct-11, for example, Oct3 / 4 (referred to herein as "Oct4") contains a POU domain (a 150 amino acid sequence conserved among Pit-1, Oct-1, Oct-2, and uric-86). See Ryan, AK and Rosenfeld, MG Genes Dev. 11, 1207-1225 (1997). In some embodiments, the variant has at least 85%, 90%, or 95% amino acid sequence identity over its entire sequence compared to a natural Oct polypeptide family member, for example, those listed above, or those listed under GenBank accession numbers NP_002692.2 (human Oct4) or NP_038661.1 (mouse Oct4). Oct polypeptides (e.g. Oct3 / 4) can be derived from human, mouse, rat, bovine, porcine, or other animals. Generally, proteins from the same species as the species of the cells to be engineered will be used.
[0051] "Klf polypeptide" refers to either a naturally occurring member of the Krüppel-like factor family (Klf), a zinc finger protein that contains an amino acid sequence similar to the Drosophila embryonic pattern regulator Krüppel, or a variant of a naturally occurring member that maintains a similar transcription factor activity (within at least 50%, 80%, or 90% of the activity) compared to the closest related naturally occurring family member, or a polypeptide that contains at least the DNA binding domain of a naturally occurring family member and may further contain a transcription activation domain. See Dang, DT, Pevsner, J. and Yang, VW, Cell Biol. 32, 1103-1121 (2000). Exemplary Klf family members include Klf1, Klf2, Klf3, Klf-4, Klf5, Klf6, Klf7, Klf8, Klf9, Klf10, Klf11, Klf12, Klf13, Klf14, Klf15, Klf16, and Klf17. Klf2 and Klf-4 were found to be factors capable of generating iPS cells in mice. Related genes Klf1 and Klf5 were similar, but less efficient. See Nakagawa, et al, Nature Biotechnology 26:101-106 (2007). In some embodiments, the variant has at least 85%, 90%, or 95% amino acid sequence identity over its entire sequence compared to a natural Klf polypeptide family member, for example, those listed above, or those listed in GenBank Accession No. CAX16088 (mouse Klf4) or CAX14962 (human Klf4). Klf polypeptides (e.g., Klf1, Klf4, and Klf5) can be derived from humans, mice, rats, cows, pigs, or other animals. In general, proteins from the same species as the species of the cells to be engineered will be used. To the extent that Klf polypeptides are described herein, they can be replaced with estrogen-related receptor beta (Essrb) polypeptides.Thus, for each Klf polypeptide embodiment described herein, the corresponding embodiment in which Essrb is used in place of the Klf4 polypeptide is also described.
[0052] "Myc polypeptide" refers to either a naturally occurring member of the Myc family (see, e.g., Adhikary, S. and Eilers, M. Nat. Rev. Mol. Cell Biol. 6:635-645 (2005)), or a variant thereof that maintains a similar transcription factor activity (within at least 50%, 80%, or 90% activity) compared to the closest related naturally occurring family member, or a polypeptide that contains at least the DNA binding domain of a naturally occurring family member and may further contain a transcription activation domain. Exemplary Myc polypeptides include, e.g., c-Myc, N-Myc, and L-Myc. In some embodiments, a variant has at least 85%, 90%, or 95% amino acid sequence identity over its entire sequence compared to a naturally occurring Myc polypeptide family member, e.g., those listed above or those listed in GenBank Accession No. CAA25015 (human Myc). Myc polypeptides (e.g., c-Myc) may be derived from human, mouse, rat, bovine, porcine, or other animals. Generally, one will use proteins of the same species as the cells being engineered.
[0053] "Sox polypeptide" refers to any naturally occurring member of the SRY-related HMG box (Sox) transcription factors characterized by the presence of a high-mobility group (HMG) domain, or a variant thereof that maintains a similar transcription factor activity (within at least 50%, 80%, or 90% activity) compared to the closest related naturally occurring family member, or a polypeptide that contains at least the DNA binding domain of the naturally occurring family member and may further contain a transcription activation domain. See, e.g., Dang, DT, et al., Int. J. Biochem. Cell Biol. 32:1103-1121 (2000). Exemplary Sox polypeptides include, e.g., Sox1, Sox-2, Sox3, Sox4, Sox5, Sox6, Sox7, Sox8, Sox9, Sox10, Sox11, Sox12, Sox13, Sox14, Sox15, Sox17, Sox18, Sox-21, and Sox30. Sox1 has been shown to give iPS cells with similar efficiency as Sox2. Genes Sox3, Sox15, and Sox18 have also been shown to generate iPS cells, but somewhat less efficiently than Sox2. See Nakagawa, et al., Nature Biotechnology 26:101-106 (2007). In some embodiments, the variant has at least 85%, 90%, or 95% amino acid sequence identity over its entire sequence compared to a natural Sox polypeptide family member, e.g., those listed above or those listed in GenBank Accession No. CAA83435 (human Sox2). Sox polypeptides (e.g., Sox1, Sox2, Sox3, Sox15, or Sox18) can be derived from human, mouse, rat, bovine, porcine, or other animals. Generally, proteins from the same species as the species of the cells to be engineered will be used.
[0054] Detailed Description of the Invention I. Introduction The present invention is based on the surprising finding that ALK5 inhibitors significantly improve the maintenance and, optionally, the induction of pluripotency in cells. The combination of an ALK5 inhibitor with a MAPK inhibitor (e.g., a MEK inhibitor, an Erk inhibitor or a p38 inhibitor), or with an FGF pathway inhibitor (e.g., an FGF receptor inhibitor), allows: Maintenance of pluripotency of cells with novel functional properties defined below that are significantly different from conventional human embryonic stem cells or induced pluripotent stem cells previously described (e.g., in U.S. Pat. Nos. 5,843; 6,200,806; and 7,029,913) and more similar to mESC characteristics; and Significantly improved efficiency and stability of cells compared to, for example, known methods for maintaining pluripotency (eg involving GSK3 and MEK inhibitors - see WO2008 / 015418). Indeed, it is surprising that inhibitors of ALK5 are effective in improving the maintenance of pluripotency, in part because the art has thus far focused on agonizing, rather than antagonizing, the TGFβ pathway to stimulate pluripotency. See, e.g., WO2008 / 056173.
[0055] The present invention provides, in part, a cell culture comprising an ALK5 inhibitor (or other TGFβ / activin pathway inhibitor) and a MAPK inhibitor or an FGF signaling pathway inhibitor, optionally comprising mammalian cells that are already pluripotent or that should be induced to pluripotency or have been induced to pluripotency in the presence of said inhibitor. Optionally, the cell culture can also include a GSK3β inhibitor and / or a leukemia inhibitory factor (LIF). Other medium components and conditions can be as generally known in the art, and can include, for example, basal medium components, vitamins, minerals, etc.
[0056] If cells can be maintained in a pluripotent state, it becomes possible to study and use such cells in many ways that would otherwise be impossible. For example, many pluripotent stem cells rapidly differentiate or die in culture, making them incompatible with screening assays, genetic engineering, and other applications in which maintaining pluripotency over a period of time or over multiple cell passages (e.g., cell divisions) is necessary or advantageous. The present invention makes it possible to avoid such problems.
[0057] II. Culture To induce or maintain pluripotency in mammalian cells, cell cultures are provided that include an ALK5 inhibitor (or other TGFβ / activin pathway inhibitor), optionally together with a MAPK (e.g., a MEK or Erk or p38 inhibitor) or an FGF signaling pathway inhibitor (e.g., an FGF receptor inhibitor). In some embodiments, cells cultured with such inhibitors have characteristics described in the Examples, including but not limited to, formation of domed colonies in culture, expression of ESC markers (e.g., Oct4, Sox2, and Nanog), nearly complete demethylation of the Oct4 promoter, expression of Rex-1 and ALP (e.g., markers of ESCs and early epiblasts that are absent in epiblasts and EpiSCs at post-implantation stages), the ability to differentiate into endoderm, neuroectoderm, and mesoderm in vitro, as well as in vivo pluripotency characteristics, such as the ability to form teratomas (e.g., in SCID mice), and, in the case of non-human cells, the ability to form chimeric offspring when injected into blastocysts and implanted into a recipient uterus. Moreover, in some embodiments, cells in culture retain such characteristics under the same culture conditions for multiple cell passages, e.g., at least 1, 2, 3, 4, 5, 7, 10, 20, 30 passages, or more.
[0058] Optionally, cell culture can also include one or both of GSk3β inhibitor and LIF.As described in the examples, the presence of LIF can improve long-term maintenance (e.g., maintenance for more than 10 passages) of pluripotent cells in some embodiments, so that a sufficient amount of LIF can be included in culture to allow long-term maintenance of pluripotency.Furthermore, a sufficient amount of GSK3β inhibitor can also be included, with or without LIF.In some embodiments, the amount of GSK3β inhibitor is sufficient to improve the efficiency of culture, i.e., the number of positive pluripotent colonies formed.
[0059] The amount of each inhibitor may vary and can be determined to provide optimal benefits depending on the exact culture conditions, the specific inhibitors used, and the type of cells cultured. In some embodiments, the culture of the present invention comprises 0.05-10 μM, such as 0.1-1 μM, such as 0.5 μM, of an ALK5 inhibitor (e.g., A-83-01, and 0.1-20 μM, such as 2-10 μM, of SB431542). The present inventors have found that TGF-βRI kinase inhibitor II [2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine] can be used as an ALK5 inhibitor described herein, for example, at a concentration of about 1.5 μM. Thus, in some embodiments, the culture of the present invention comprises 0.05-20 μM, such as 0.1-10 μM, of a TGF-βRI kinase inhibitor II. In some embodiments, the culture of the present invention comprises 10 nM to 5 μM, such as 50 nM to 1 μM, of an FGF pathway inhibitor (e.g., PD173074). In some embodiments, the culture of the present invention comprises 0.05 to 50 μM, such as 0.1 to 5 μM, such as 0.5 μM, of an MEK inhibitor (e.g., PD0325901). In some embodiments, the culture of the present invention comprises 0.05 to 20 μM, such as 0.5 to 5 μM, such as 3 μM, of a GSK3β inhibitor (e.g., CHIR99021).
[0060] TGFβ receptor (e.g., ALK5) inhibitors can include antibodies against TGFβ receptor (e.g., ALK5), dominant negative mutants of TGFβ receptor (e.g., ALK5), and antisense nucleic acids targeting TGFβ receptor (e.g., ALK5).Exemplary TGFβ receptor / ALK5 inhibitors include SB431542 (see, e.g., Inman, et al., Molecular Pharmacology 62(1):65-74 (2002)), A-83-01, which is also known as 3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (see, e.g., Tojo, et al., Cancer Science 96(11):791-800 (2005)).commercially available, e.g., from Toicris Biosciences; TGF-βRI kinase inhibitor II [2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine]; 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, Wnt3a / BIO (see, e.g., Dalton, et al., WO 2008 / 094597, incorporated herein by reference), BMP4 (Dalton, supra), GW788388 (-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide) (see, e.g., Gellibert, et al., Journal of Medicinal Chemistry 49(7):2210-2221 (2006)), SM16 (see, e.g., Suzuki, et al., Cancer Research 67(5):2351-2359 (2007)), IN-1130 (3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide) (see, e.g., Kim, et al., Xenobiotica 38(3):325-339 (2008)), GW6604 (2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine) (see, e.g., de Gouville, et al., Drug News Perspective 19(2):85-90 (2006)), SB-505124 (2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride) (see, e.g., DaCosta, et al., Molecular Pharmacology 65(3):744-752 (2004)), and pyrimidine derivatives (e.g., those listed in Stiefl, et al., WO2008 / 006583, which is incorporated herein by reference).Without intending to limit the scope of the present invention, it is believed that ALK5 inhibitors affect the mesenchymal to epithelial transformation / transition (MET) process. TGFβ / activin pathway is the pathway that drives epithelial to mesenchymal transition (EMT). Therefore, inhibiting TGFβ / activin pathway can facilitate MET (i.e. reprogramming) process.
[0061] Considering the data described herein showing the effect of inhibiting ALK5, it is believed that inhibiting TGFβ / activin pathway will have a similar effect. Therefore, any inhibitor of TGFβ / activin pathway (e.g., upstream or downstream inhibitor) can be used in combination with or instead of the ALK5 inhibitors described in each paragraph of this specification. Exemplary TGFβ / activin pathway inhibitors include, but are not limited to, TGFβ receptor inhibitors, inhibitors of SMAD2 / 3 phosphorylation, inhibitors of SMAD2 / 3 and SMAD4 interaction, and activators / agonists of SMAD6 and SMAD7. Furthermore, it will be understood by those skilled in the art that the categorization described below is merely for organizational purposes, and that a compound can affect one or more points in the pathway, and therefore a compound can function in more than one of the defined categories.
[0062] TGFβ receptor inhibitors can include antibodies against TGFβ receptors, dominant negative mutants of TGFβ receptors, and antisense nucleic acids targeting TGFβ receptors. Specific examples of inhibitors include SU5416; 2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride (SB-505124); lerdelimumb (CAT-152); metelimumab (CAT-192); GC-1008; ID11; AP-12009; AP-11014; LY550410; LY580276; LY364947; LY210 These include, but are not limited to, 9761; SB-505124; SB-431542; SD-208; SM16; NPC-30345; Ki26894; SB-203580; SD-093; Gleevec; 3,5,7,2',4'-pentahydroxyflavone (morin); activin-M108A; P144; soluble TBR2-Fc; and antisense transfected tumor cells targeting the TGFβ receptor (e.g., Wrzesinski, (see, e.g., Kaminska, et al., Acta Biochimica Polonica 52(2):329-337 (2005); and Chang, et al., Frontiers in Bioscience 12:4393-4401 (2007)).
[0063] Inhibitors of SMAD2 / 3 phosphorylation can include antibodies against SMAD2 or SMAD3, dominant negative mutants of SMAD2 or SMAD3, and antisense nucleic acids targeting SMAD2 or SMAD3. Specific examples of inhibitors include PD169316; SB203580; SB-431542; LY364947; A77-01; and 3,5,7,2',4'-pentahydroxyflavone (morin) (see, e.g., Wrzesinski, supra; Kaminska, supra; Shimanuki, et al., Oncogene 26:3311-3320 (2007); and Kataoka, et al., EP1992360, which are incorporated herein by reference).
[0064] Inhibitors of SMAD2 / 3 and smad4 interaction can include antibodies against SMAD2, SMAD3 and / or smad4, dominant negative mutants of SMAD2, SMAD3 and / or smad4, and antisense nucleic acids targeting SMAD2, SMAD3 and / or smad4. Specific examples of inhibitors of SMAD2 / 3 and SMAD4 interaction include, but are not limited to, Trx-SARA, Trx-xFoxH1b and Trx-Lef1 (see, e.g., Cui, et al., Oncogene 24:3864-3874 (2005) and Zhao, et al., Molecular Biology of the Cell, 17:3819-3831 (2006)).
[0065] Inhibitors of MEK can include antibodies to MEK, dominant negative mutants of MEK, and antisense nucleic acids targeted to MEK. Specific examples of MEK inhibitors include PD0325901 (see, e.g., Rinehart, et al., Journal of Clinical Oncology 22:4456-4462 (2004)), PD98059 (available, e.g., from Cell Signaling Technology), U0126 (available, e.g., from Cell Signaling Technology), SL327 (available, e.g., from Sigma-Aldrich), ARRY-162 (available, e.g., from Array Biopharma), PD184161 (see, e.g., Klein, et al., Neoplasia 8:1-8 (2006)), PD184352 (CI-1040) (see, e.g., Mattingly, et al., The Journal of Pharmacology and Experimental Therapeutics 316:456-465 (2006)), sunitinib (see, e.g., Voss, et al., The Journal of Clinical Oncology 22:4456-4462 (2004)), which are incorporated by reference herein. US2008004287), sorafenib (Voss, supra), vandetanib (Voss, supra), pazopanib (e.g., see Voss, supra), axitinib (Voss, supra) and PTK787 (Voss, supra).
[0066] Several MEK inhibitors are currently undergoing clinical trial evaluation: CI-1040 has been evaluated in phase I and phase II clinical trials for cancer (see, e.g., Rinehart, et al., Journal of Clinical Oncology 22(22):4456-4462 (2004)). Other MEK inhibitors being evaluated in clinical trials include PD184352 (see, e.g., English, et al., Trends in Pharmaceutical Sciences 23(1):40-45 (2002)), BAY43-9006 (see, e.g., Chow, et al., Cytometry (Communications in Clinical Cytometry) 46:72-78 (2001)), PD-325901 (also PD0325901), GSK1120212, ARRY-438162, RDEA119, AZD6244 (also ARRY-142886 or ARRY-886), RO5126766, XL518, and AZD8330 (also ARRY-704) (see, e.g., clinicaltrials.gov on the World Wide Web from the National Institutes of (See information available from the National Cancer Institute at cancer.gov / clinicaltrials, as well as from the National Cancer Institute on the World Wide Web at cancer.gov / clinicaltrials.)
[0067] p38 (also known as CSBP, mHOG1, RK and SAPK2) inhibitors can include antibodies against p38, dominant negative mutants of p38, and antisense nucleic acids that target p38. Specific examples of inhibitors include SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole); SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5(4-pyridyl)-1H-imidazole); SB220025; N-(3-tert-butyl-1-methyl-5-pyrazolyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea; RPR200765A; UX-745; UX-702; UX-850; SCIO-469; RWJ-67657 (RW Johnson Pharmaceutical Research Institute); RDP-58 (SangStat Medical Corp.; acquired by Genzyme Corp.); Scios-323 (SCIO 323; Scios Inc.); Scios-469 (SCIO-469; Scios Inc.); MKK3 / MKK6 inhibitors (Signal Research Division); p38 / MEK regulators (Signal Research Division); SB-210313 analogs; SB-238039; HEP-689 (SB235699); SB-239063; SB-239065; SB-242235 (SmithKline Beecham Pharmaceuticals); VX-702 and VX-745 (Vertex Pharmaceuticals Inc.); AMG-548 (Amgen Inc.); Astex p38 kinase inhibitors (Astex Technology Ltd.); RPR-200765 analogs (Aventis SA); Bayer p38 kinase inhibitors (Bayer Corp.); BIRB-796 (Boehringer Ingelheim Pharmaceuticals Inc.); Celltech p38 MAP kinase inhibitors (Celltech Group plc.);FR-167653(Fujisawa Pharmaceutical Co. Ltd.); SB-681323 and SB-281832 (GlaxoSmithKline plc); LEO Pharmaceuticals MAP kinase inhibitors (LEO Pharma A / S); Merck Co. p38 MAP kinase inhibitors (Merck research Laboratories); SC-040 and SC-XX906 (Monsanto Co.); adenosine A3 antagonists (Novartis AG); p38 MAP kinase inhibitors (Novartis Pharma AG); CNI-1493 (Picower Institute for Medical Research); RPR-200765A (Rhone-Poulenc Rorer Ltd.); and Roche p38 MAP kinase inhibitors (e.g., RO3201195 and RO4402257; Roche Bioscience). See, e.g., Roux, et al., Microbiology and Molecular Biology Reviews 68(2):320-344 (2004); Engelman, et al., Journal of Biological Chemistry 273(48):32111-32120 (1998); Jackson, et al., Journal of Pharmacology and Experimental Therapeutics 284(2):687-692 (1998); Kramer, et al., Journal of Biological Chemistry 271(44):27723-27729 (1996); and Menko, et al., US20080193504.
[0068] Further inhibitors of p38 include, but are not limited to, 1,5-diaryl substituted pyrazole and substituted pyrazole compounds (US6509361 and US6335336); substituted pyridyl compounds (US20030139462); quinazoline derivatives (US6541477, US6184226, US6509363 and US6635644); aryl ureas and heteroaryl analogues (US6344476); heterocyclic ureas (WO1999 / 32110); other urea compounds (WO1999 / 32463, WO1998 / 52558, WO1999 / 00357 and WO1999 / 58502); and substituted imidazole and triazole compounds (US6560871 and US6599910).
[0069] Erk inhibitors can include antibodies against Erk, dominant negative mutants of Erk, and antisense nucleic acids that target Erk.Specific examples of Erk inhibitors include, but are not limited to, PD98059 (see, for example, Zhu, et al., Oncogene 23:4984-4992 (2004)), U0126 (see, Zhu, supra), FR180204 (see, for example, Ohori, Drug News Perspective 21(5):245-250 (2008)), sunitinib (see, for example, Ma, et al., US2008004287, which is incorporated herein by reference), sorafenib (see, Ma, supra), vandetanib (see, Ma, supra), pazopanib (see, Ma, supra), axitinib (see, Ma, supra) and PTK787 (see, Ma, supra). Erk inhibitors can include molecules that inhibit only Erk or that inhibit a second target as well. For example, in some embodiments, Erk inhibitors include: TIFF2024098047000001.tif46128[in the formula, R1 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 6-10 Aryl-C 0-4 Alkyl, C 5-10Heteroaryl- 0-4 Alkyl, C 3-10 Cycloalkyl-C 0-4 Alkyl and C 3-10 Heterocycloalkyl-C 0-4 alkyl; where any alkyl or alkenyl in R is selected from halo, hydroxy, C 1-6 and -NR2R3, optionally substituted with 1 to 3 groups independently selected from alkyl and -NR2R3; any aryl, heteroaryl, cycloalkyl or heterocycloalkyl in R1 is optionally substituted with halo, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, halo-substituted alkyl, halo-substituted alkoxy, -XNR2R3, -XOXNR2R3, -XNR2S(O) 0-2 R3, -XC(O)NR2R3, -XNR2C(O)XOR2, -XNR2C(O)NR2R3, -XNR2XNR2R3, -XC(O)NR2XNR2R3, -XNR2XOR2, -XOR2, -XNR2C(=NR2)NR2R3, -XS(O) 0-2 R4, -XNR2C(O)R2, -XNR2C(O)XNR2R3, -XNR2C(O)R4, -XC(O)R4, -XR4, -XC(O)OR3 and -XS(O) 0-2 Optionally, 1 to 3 groups selected from NR2R3; where X is a bond or C 1-4 alkylene; R and R are hydrogen, C 1-6 Alkyl and C 3-12 cycloalkyl; and R4 is independently selected from C 1-6 C optionally substituted with 1 to 3 groups selected from alkyl, -XNR2R3, -XNR2XNR2R2, XNR2XOR2, and -XOR2 3-10 heterocycloalkyl; where X, R2 and R3 are as defined above. and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and pharma- ceutically acceptable salts and solvates (e.g., hydrates) of such compounds, or as otherwise described in WO06 / 135824.
[0070] Inhibitors of FGF signaling pathway include, but are not limited to, FGF receptor inhibitors. FGF receptor (FGFR) inhibitors can include antibodies against FGFR, dominant negative mutants of FGFR, and antisense nucleic acids that target FGFR. Specific examples of FGFR inhibitors include, but are not limited to, SU6668 (see, e.g., Klenke, BMC Cancer 7:49 (2007)), SU5402 (3-[3-(2-carboxyethyl)-4-methylpyrrole-2-methylidenyl]-2-indolinone) and PD173074 (see, e.g., Bansal, et al., J. Neuro. Res. 74(4):486-493 (2003)).
[0071] Inhibitors of GSK3 can include antibodies to GSK3, dominant negative mutants of GSK3, and antisense nucleic acids targeted to GSK3. Specific examples of GSK3 inhibitors include CHIR99021, CHIR98014, AR-A014418 (see, e.g., Gould et al., The International Journal of Neuropsychopharmacology 7:387-390 (2004)), CT99021 (see, e.g., Wagman, Current Pharmaceutical Design 10:1105-1137 (2004)), CT20026 (see, Wagman, supra), SB216763 (see, e.g., Martin, et al., Nature Immunology 6:777-784 (2005)), AR-A014418 (see, e.g., Noble, et al., PNAS 102:6990-6995 (2005)), lithium (see, e.g., Gould, et al., Pharmacological Research 48:49-53 (2005)), and the like. (2003)), SB415286 (see, e.g., Frame, et al., Biochemical Journal 359:1-16 (2001)), and TDZD-8 (see, e.g., Chin, et al., Molecular Brain Research, 137(1-2):193-201 (2005)).Further exemplary GSK3 inhibitors available from Calbiochem (see, e.g., Dalton, et al., WO2008 / 094597, incorporated herein by reference) include BIO(2'Z,3'£)-6-bromoindirubin-3'-oxime (GSK3 inhibitor IX); BIO-acetoxime(2'Z,3'E)-6-bromoindirubin-3'-acetoxime (GSK3 inhibitor X); (5-methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine (GSK3 inhibitor XIII); pyridocarbazole-cyclopentadienyl ruthenium complex (GSK3 inhibitor XV); TDZD-8, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (GSK3 beta inhibitor I); 2-thio(3-iodobenzyl )-5-(1-pyridyl)-[1,3,4]-oxadiazole (GSK-3 beta inhibitor II);OTDZT, 2,4-dibenzyl-5-oxothiadiazolidine-3-thione (GSK-3 beta inhibitor III);alpha-4-dibromoacetophenone (GSK-3 beta inhibitor VII);AR-AO14418, N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea (GSK-3 beta inhibitor VIII);3-(1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-yl-pyrrole-2,5-dione (GSK-3 beta inhibitor XI);TWS1 19, pyrrolopyrimidine compounds (GSK3 beta inhibitor XII); L803, H-KEAPPAPPQSpP-NH2 (SEQ ID NO: 1) or its myristoylated form (GSK3 beta inhibitor XIII); 2-chloro-1-(4,5-dibromo-thiophen-2-yl)-ethanone (GSK3 beta inhibitor VI); AR-AO144-18; SB216763; and SB415286. Residues of GSK3b that interact with inhibitors have been identified. See, for example, Bertrand et al., J Mol Biol. 333(2):393-407 (2003).
[0072] When the inhibitor of a certain gene product is described herein, it should be understood that the inhibitor can be replaced with siRNA that targets the gene that codes for the gene product.For example, the present invention contemplates using siRNA that inhibits the expression of ALK5 instead of ALK5 inhibitor.Similarly, MEK inhibitor, Erk inhibitor, p38 inhibitor, FGF receptor inhibitor, and GSK3β inhibitor can be replaced with MEK siRNA, Erk siRNA, p38 siRNA, FGF receptor siRNA, and GSK3β siRNA, respectively.In addition, inhibitory antibodies (e.g., humanized antibodies or chimeric antibodies) can be used as inhibitors of ALK5, MEK, Erk, p38, FGF receptor, and GSK3β.
[0073] In some embodiments, cells are first cultured with epigenetic modifiers, and then cultured without the modifiers but with inhibitors as described herein (e.g., AKL5 inhibitors, MEK inhibitors, Erk inhibitors, p38 inhibitors, FGF receptor inhibitors, and GSK3β inhibitors, leukemia inhibitory factor (LIF), etc.). Exemplary epigenetic regulators include inhibitors of histone H3K4 demethylation or activators of H3K4 methylation. Exemplary epigenetic modifiers include, for example, histone demethylase inhibitors, such as LSD1 inhibitors (e.g., parnate) or MAO inhibitors.
[0074] The terms "histone deacetylase inhibitor", "inhibitor of histone deacetylase" and "HDAC inhibitor" refer to compounds capable of interacting with histone deacetylase and inhibiting its enzymatic activity. "Inhibiting histone deacetylase enzymatic activity" means reducing the ability of histone deacetylase to remove acetyl groups from histones. In some embodiments, such reduction in histone deacetylase activity is at least about 50%, more preferably at least about 75%, and even more preferably at least about 90%. In other preferred embodiments, the histone deacetylase activity is reduced by at least 95%, and more preferably at least 99%.
[0075] Representative HDAC inhibitors include, for example, butyrate, MS-27-275, SAHA, trichostatin A, apicidin, oxanflatin, FK228, and trapoxin. Based on their structure, these inhibitors can be divided into several classes, such as short-chain fatty acids (butyrates and valproic acid), hydroxamic acids (trichostatin A and SAHA), cyclic tetrapeptides (depsipeptides), benzamides (MS-27-275), and epoxide-containing agents (trapoxin). Most of them reversibly inhibit HDACs, except for trapoxin, which has an epoxy group capable of irreversibly alkylating HDACs. Reversible inhibitors generally have long aliphatic tails containing nucleophilic ends such as -SH or -OH that interact with the active zinc center located at the bottom of the HDAC binding pocket. Other HDAC inhibitors are emerging based on modifications of the listed structures. The majority of the new agents are derivatives of hydroxamic acids, including amide analogs of trichostatin A (TSA) and the thio / phosphorus-based SAHA. Replacement of the amide bond in the MS-27-275 structure with sulfonamides has led to the discovery of a new class of potent HDAC inhibitors. Promising HDAC inhibitors that have entered clinical trials include the hydroxamic acid derivative LAQ824, the butyric acid derivative Titan, valproic acid, MS-27-275, SAHA, and the depsipeptide FK228.
[0076] Histone demethylase inhibitors include inhibitors against lysine-specific demethylase I (LSD1; also known as lysine-specific histone demethylase, BHC1 10 and KIAA0601). International patent application WO2006 / 071608 is directed to methods for monitoring eukaryotic histone demethylase activity, for upregulating and downregulating methylated histone-activated genes, and for treating or preventing disease (e.g., hyperproliferative diseases such as cancer) by modulating histone demethylase protein levels or activity. Given the importance of gene regulation and the effect that inhibiting or modulating LSD1 may have on gene regulation, inhibitors of this enzyme may have important therapeutic potential; Bi, X. et al., Bioorg. Med. Chem. Lett. 16:3229-3232 (2006) and international patent applications WO2007 / 021839 and WO2008 / 127734 describe certain compounds useful as inhibitors of LSD1.
[0077] The present invention also provides a culture medium for maintaining the pluripotency of cells. The cell culture medium may not contain cells. The culture medium may contain the above-mentioned culture medium contents even if it is accompanied by cells. Such a medium is useful for culturing the cells described herein.
[0078] As described later in this specification, the cells in the culture can be selected from embryonic stem cells (e.g., human embryonic stem cells (hESCs), primate embryonic stem cells, rat embryonic stem cells, or embryonic stem cells derived from other animals, optionally non-mouse embryonic stem cells). Alternatively, the cells include induced pluripotent stem cells (iPSCs). In some embodiments, the iPSCs are derived from human, primate, rat, or mouse, or from non-mouse animals. The iPSCs may have just been generated from non-pluripotent cells and have not yet undergone a new cell division, or the cells may have already been maintained as iPSCs for 1, 2, 3, 4, 5, 7, 10, 20 or more cell divisions or passages. In other words, the cell culture can contain iPSCs that were previously generated (e.g., 1 week, 1 month, or more). One advantage of the small molecule combinations described herein, in addition to their use in reprogramming, is that they allow the desired pluripotency to be maintained for a period of time that may be infinite.
[0079] The present invention provides pluripotent cells mixed with one or more inhibitors described herein. In some embodiments, the compound is present in the mixture at a concentration sufficient to induce pluripotency or to improve the efficiency of induction of pluripotency. For example, in some embodiments, the compound is present at a concentration of at least 0.1 nM, such as at least 1, 10, 100, 1000, 10000, or 100000 nM, such as 0.1 nM to 100000 nM, such as 1 nM to 10000 nM, such as 10 nM to 10000 nM, 0.01 μM to 5 μM, 0.1 μM to 5 μM. For example, A-83-01 can be used at a concentration of about 0.1 μM to about 0.5 μM, such as 0.25 μM to about 0.5 μM. In some embodiments, the concentration of A-83-01 is 0.25 μM. In some embodiments, the concentration of A-83-01 is 0.5 μM. CHIR99021 can be used at a concentration of about 3 μM. PD325901 can be used at a concentration of about 0.5 μM. PD173074 can be used at a concentration of about 0.1 μM. In some embodiments, the mixture is contained in a synthetic container (e.g., a test tube, a petri dish, etc.). Thus, in some embodiments, the cell is an isolated cell (not part of an animal). In some embodiments, the cell is isolated from an animal (human or non-human), placed in a container, and contacted with one or more compounds described herein. The cell can then be cultured and, optionally, stimulated to become a specific cell type or lineage, and then optionally inserted back into the same or a different animal.
[0080] In some embodiments, the cells contain expression cassettes for heterologous expression of at least one or more of an Oct polypeptide, a Myc polypeptide, a Sox polypeptide, and a Klf polypeptide. In some embodiments, the cells do not contain expression cassettes for expressing any of the Oct, Myc, Sox, or Klf polypeptides. Cells with or without such expression cassettes are useful, for example, in the screening methods described herein.
[0081] III.Cells The cells may be pluripotent prior to initial contact with an inhibitor of the invention, or pluripotency may be induced after contacting the cells with one or more inhibitors of the invention (e.g., by introduction of appropriate transcription factors and / or by contact with an appropriate small molecule to induce pluripotency).
[0082] Any animal cell can be used in the method of the present invention.Thus, for example, in some embodiments, the cell is a mammalian cell.Exemplary mammalian cells include, but are not limited to, human or non-human cells, including rat, mouse (e.g., SCID mouse or other mouse), pig, cow, sheep, dog, cat, and primate (e.g., rhesus monkey, chimpanzee, etc.).
[0083] The pluripotent cells used according to the method of the present invention can be natural stem cells or induced pluripotent cells. Exemplary natural stem cells include, for example, embryonic stem cells. Methods for isolating embryonic stem cells are well known. For example, Matsui et al., Cell 70:841, 1992; Thomson et al., US Pat. No. 5,843,780; Thomson et al., Science 282:114, 1998; Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998; Shamblott et al., U.S. Patent No. 6,090,622; Reubinoff et al., Nat. Biotech. 18:399, 2000; PCT WO00 / 27995, Iannaccone et al., Dev. Biol. 163:288, 1994; Loring et al., PCT WO99 / 27076, Pain et al., Development 122:2339, See, U.S. Patent No. 5,340,740; U.S. Patent No. 5,656,479; Wheeler et al., Reprod. Fertil. Dev. 6:563, 1994; Shim et al., Biol. Reprod. 57:1089, 1997. In some embodiments, stem cells are derived from (e.g., obtained from) blastocysts, which are then cultured in the presence of at least an ALK5 inhibitor and an Erk or MEK inhibitor, optionally with other inhibitors as described herein.
[0084] There are currently several methods reported for inducing pluripotency in cells. Pluripotency can be induced, for example, by introducing transcription factors or by inducing or mimicking the expression of certain transcription factors. In some embodiments, one or more of the following transcription factors are expressed endogenously or recombinantly (for example, by introducing a heterologous expression cassette that expresses one or more transcription factors). Exemplary techniques for inducing pluripotency include, but are not limited to, introducing at least one or more expression cassettes for expressing at least one of Oct3 / 4, Sox2, c-Myc, and Klf4 (see, for example, Takahashi, Cell 131(5):861-872 (2007); Cell Stem Cell 2, 10-12 (2008)), optionally with one or more small molecules (for example, but not limited to, agents such as BIX01294 that inhibit H3K9 methylation, for example G9a histone methyltransferase). See, e.g., Kubicek et al., Mol. Cell 473-481 (2007).
[0085] The pluripotent cells of the present invention can be characterized by several criteria. In addition to the gene expression, methylation, and in vitro and in vivo characteristics described herein, the pluripotent cells of the present invention are believed to maintain pluripotency for at least one cell division (e.g., 1, 2, 3, 4, 5, 10, 20, etc.) in the presence of leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP), or under the inhibition of TGFβ and activin signaling pathway, under the inhibition of MAPK signaling pathway, and optionally under the inhibition of FGF pathway.For example, as described herein, animal cells (e.g., human cells and rat cells) contacted with ALK5 inhibitor and MEK inhibitor maintain pluripotency over multiple divisions. Furthermore, as described herein, inhibition of TGFβ and activin signaling pathways (e.g., TGFβ signaling), in combination with inhibition of MEK, FGFR, and GSK3, can promote partial conversion of EpiSCs to an mESC-like state with robust reprogramming activity. In contrast, conventional hESCs, epiblast stem cells (EpiSCs), and human induced pluripotent cells cultured under conventional conditions differentiate when contacted with an inhibitor of ALK5. See, e.g., Saha, et al., Biophys. J. 94:4123-4133 (2008). Conventional hESCs, EpiSCs and human induced pluripotent cells cultured under conventional culture conditions appear to depend on MAPK, FGF and TGFβ / Activin / Nodal pathway activity for self-renewal and have been reported to rapidly differentiate when treated with MEK, FGFR and / or ALK4 / 5 / 7 inhibitors (Brons et al., Nature 448, 191-195, 2007;Li et al., Differentiation 75, 299-307, 2007;Peerani et al., EMBO J 26, 4744-4755, 2007;Tesar et al., Nature 448, 196-199, 2007).The present inventors have also found that the cells of the present invention (e.g., human or rat cells cultured as described in the Examples) maintain pluripotency (i.e., do not differentiate) in the presence of an inhibitor of the FGF signaling pathway (e.g., PD173074). In contrast, hESCs, EpiSCs, and human induced pluripotent cells cultured under conventional conditions differentiate when contacted with PD173074. Of note, mESCs do not differentiate when contacted with PD173074. Thus, the cells of the present invention (e.g., cultured as described herein) are closer to mESCs than conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells. The cells of the present invention have a more compact, dome-shaped colony morphology, similar to mESCs, whereas conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells have a flattened colony morphology. The cells of the present invention, like mESCs, have the ability to give rise to all cell types in vitro and contribute to the whole animal, including the germ line, in vivo when returned to blastocysts. In contrast, conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells do not have the ability to incorporate into the inner cell mass (ICM) and contribute to chimerism. It will be understood that the methods described herein can be used to generate other animal cells with similar characteristics, in addition to rats and humans. Exemplary additional animal cells include, for example, dog, cat, pig, cow, sheep, goat, monkey, and chimpanzee.
[0086] Certain markers are useful for distinguishing the cells of the present invention from conventionally cultured hESCs, EpiSCs and human induced pluripotent cells.For example, Stra8, Dppa3, Gbx2, Pecam1 and Klf4 are expressed at higher levels in the human cells of the present invention than in conventionally cultured hESCs, epiSCs and human induced pluripotent cells.In contrast, many lineage-specific genes, such as Foxa2, Otx2, Lefty1, Gata6, Sox17, Cer1, are expressed at higher levels in epiSCs and conventional human ES cells than in the cells of the present invention. Conventionally cultured human iPSC or ESC cells differentiate when treated with MEK, FGFR and / or ALK4 / 5 / 7 inhibitors (Brons et al., Nature 448, 191-195, 2007; Li et al., Differentiation 75, 299-307, 2007; Peerani et al., EMBO J 26, 4744-4755, 2007; Tesar et al., Nature 448, 196-199, 2007).
[0087] In particular, Gbx2, Dppa3 and Klf4 are useful markers for characterizing the pluripotent animal cells of the present invention. These markers are highly expressed in the pluripotent cells of the present invention. For example, in some embodiments, the cells of the present invention express these markers at least twice as high as their levels in conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells, such as Hues9 cells (hES facility, Harvard University, http: / / mcb.harvard.edu / melton / hues / ). In some embodiments, the expression levels of these markers in the pluripotent cells of the present invention are at least 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold or more. Other useful markers include the ICM marker Rex1.
[0088] In some embodiments, Gbx2 is expressed in the pluripotent cells of the invention at a level at least 5-fold higher than in Hues9 cells. In some embodiments, Klf4 is expressed in the pluripotent cells of the invention at a level at least 2.5-fold higher than in Hues9 cells. In some embodiments, Dppa3 is expressed in the pluripotent cells of the invention at a level at least 2-fold higher than in Hues9 cells.
[0089] Another useful marker for the pluripotent cells of the present invention is E-cadherin.Without intending to limit the scope of the present invention, it is believed that E-cadherin plays a role in the pluripotency of the cells of the present invention.In some embodiments, E-cadherin is expressed in the pluripotent cells of the present invention at a level twice that of Hues9 cells.
[0090] Other typical pluripotency markers, such as Oct4, Sox2, Nanog, SSEA-1, SSEA-3, SSEA4, TRA-1-61, TRA-1-81, and alkaline phosphatase (ALP), can be used to characterize the cells of the present invention. These typical pluripotency markers, or a subset thereof, can help distinguish the pluripotent cells of the present invention from conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells.
[0091] To characterize the cells of the present invention, methods known in the art can be used. Gene expression levels can be detected, for example, by real-time PCR or real-time RT-PCR (e.g., to detect mRNA) and / or by Western blot or other protein detection techniques.
[0092] The pluripotent cells of the present invention differentiate towards mesodermal lineages in response to BMP treatment, whereas conventionally cultured hESCs, EpiSCs and human induced pluripotent cells generate trophoblast or primitive endoderm cells (Brons et al., Nature 448, 191-195, 2007; D'Amour et al., Nat Biotechnol 23, 1534-1541, 2005; Xu et al., Nat Biotechnol 20, 1261-1264, 2002).
[0093] IV. Transformation If transformed cells are desired (e.g., to generate iPSCs or to express a desired protein or nucleic acid), the cells contacted with the inhibitors of the present invention (e.g., ALK5 inhibitors, MAPK inhibitors, FGF pathway inhibitors, and optionally GSK3β inhibitors) may be transformed before and / or after contact. For example, one advantage of the present invention is that it allows for the maintenance of pluripotent cells through multiple cell passages, thus allowing the cells to be manipulated and subsequently selected for progeny while maintaining their pluripotent characteristics. This is particularly useful for the generation of transgenic animals (including the generation of knockout animals by sequence-specific recombination events as described herein).
[0094] The present invention relies on routine techniques in the field of recombinant genetics. Basic textbooks that disclose the general methods useful in the present invention include Sambrook et al. "Molecular Cloning, A Laboratory Manual" (3rd ed., 2001); Kriegler "Gene Transfer and Expression: A Laboratory Manual" (1990); and "Current Protocols in Molecular Biology" (Ausubel et al., eds., 1994).
[0095] In some embodiments where positive expression of a protein is desired, the species of the cell and the species of the protein to be expressed are the same. For example, if mouse cells are used, the mouse orthologue is introduced into the cell. If human cells are used, the human orthologue is introduced into the cell.
[0096] It will be understood that where two or more proteins are to be expressed in a cell, one or more expression cassettes can be used, for example, where one expression cassette is to express multiple polypeptides, a polycistronic expression cassette can be used.
[0097] A. Plasmid Vectors In certain embodiments, it is contemplated that a plasmid vector is used to transform a host cell. Generally, a plasmid vector containing a replicon and a control sequence derived from a species compatible with the host cell is used in connection with these hosts. The vector can have a replication site and a marking sequence that can provide phenotypic selection of transformed cells.
[0098] B. Viral Vectors The ability of certain viruses to infect or enter cells by receptor-mediated endocytosis and integrate into the host cell genome to stably and efficiently express viral genes has made them attractive candidates for introducing foreign nucleic acids into cells (e.g., mammalian cells). Non-limiting examples of viral vectors that can be used to deliver the nucleic acids of the present invention are described below.
[0099] i. Adenovirus Vectors One particular method for delivering nucleic acids uses adenoviral expression vectors. Adenoviral vectors are known to have a low capacity for integration into genomic DNA, but this property is offset by the high gene transfer efficiency obtained with these vectors. "Adenoviral expression vector" is intended to encompass constructs that contain sufficient adenoviral sequences to (a) support packaging of the construct and (b) ultimately express the tissue- or cell-specific construct cloned therein. Knowledge of the genetic organization of adenovirus, a linear, double-stranded DNA virus of .about.36 kb, allows replacement of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus et al., Seminar in Virology, 200(2):535-546, 1992).
[0100] ii. AAV vectors Nucleic acids can be introduced into cells using adenovirus assisted transfection. Increased transfection efficiency has been reported in cell systems using the adenovirus coupled system (Kelleher and Vos, Biotechniques, 17(6):1110-7, 1994;Cotten et al., Proc Natl Acad Sci USA, 89(13):6094-6098, 1992;Curiel, Nat Immun, 13(2-3):141-64, 1994). Adeno-associated virus (AAV) is an attractive vector system. rAAV vectors are useful because they have a high integration frequency and can infect non-dividing cells, making them useful for delivering genes into mammalian cells, for example in tissue culture (Muzyczka, Curr Top Microbiol Immunol, 158:97-129, 1992) or in vivo. Details regarding the construction and use of rAAV vectors are described in U.S. Patent Nos. 5,139,941 and 4,797,368, each of which is incorporated herein by reference.
[0101] iii. Retroviral vectors Retroviruses are promising gene delivery vectors because of their ability to integrate genes into the host genome, to carry large amounts of foreign genetic material, to infect a wide range of species and cell types, and to be packaged in specialized cell lines (Miller et al., Am. J. Clin. Oncol., 15(3):216-221, 1992).
[0102] To construct a retroviral vector, a nucleic acid (e.g., encoding a gene of interest) is inserted into the viral genome in place of certain viral sequences to generate a replication-deficient virus. To produce viral particles, a packaging cell line is constructed that contains the gag, pol, and env genes but lacks the LTR and packaging components (Mann et al., Cell, 33:153-159, 1983). When a recombinant plasmid containing a cDNA together with retroviral LTRs and packaging sequences is introduced into a specialized cell line (e.g., by calcium phosphate precipitation), the packaging sequences allow the RNA transcripts of the recombinant plasmid to be packaged into viral particles that are then secreted into the culture medium (Nicolas and Rubinstein, "Vectors: A survey of molecular cloning vectors and their uses," Rodriguez and Denhardt, eds., Stoneham: Butterworth, pp. 494-513 (1988); Temin, "Gene Transfer," Kucherlapati, ed., New York: Plenum Press, pp. 149-188 (1986); Mann et al., Cell, 33:153-159, 1983). The medium containing the recombinant retrovirus is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors can infect a wide variety of cell types. However, integration and stable expression typically require the division of host cells (Paskind et al., Virology, 67:242-248, 1975).
[0103] Lentivirus is a complex retrovirus that contains other genes with regulatory or structural functions in addition to the general retroviral genes gag, pol and env.Lentivirus vectors are well known in the art (see, for example, Naldini et al., Science, 272(5259):263-267, 1996; Zufferey et al., Nat Biotechnol, 15(9):871-875, 1997; Blomer et al., J Virol., 71(9):6641-6649, 1997; U.S. Patent Nos. 6,013,516 and 5,994,136).Examples of lentivirus include human immunodeficiency virus: HIV-1, HIV-2, and simian immunodeficiency virus, i.e., SIV. Lentiviral vectors have been generated by multiple attenuation of HIV virulence genes, for example the genes env, vif, vpr, vpu and nef are deleted, rendering the vector biologically safe.
[0104] Recombinant lentiviral vectors have the ability to infect non-dividing cells and can be used for gene transfer and expression of nucleic acid sequences in vivo and ex vivo. For example, recombinant lentiviruses capable of infecting non-dividing cells (wherein a suitable host cell is transfected with two or more vectors carrying packaging functions, i.e., gag, pol and env, and rev and tat) are described in U.S. Patent No. 5,994,136, which is incorporated herein by reference. Recombinant viruses can be targeted by linking the envelope protein with an antibody or a specific ligand for targeting a receptor on a specific cell type. For example, a sequence of interest (including a regulatory region) can be inserted into a viral vector together with another gene that codes for a ligand of a receptor on a specific target cell, making the vector target specific.
[0105] iv. Delivery using modified viruses The nucleic acid to be delivered can be housed in an infectious virus engineered to express a specific binding ligand. The virus particle will then specifically bind to the cognate receptor of the target cell and deliver its contents to the cell. A novel approach designed to allow specific targeting of retroviral vectors has been developed based on the chemical modification of retroviruses by chemical addition of lactose residues to the viral envelope. This modification can allow specific infection of liver cells via sialoglycoprotein receptors.
[0106] Another approach to targeting recombinant retroviruses was designed, which used biotinylated antibodies against retroviral envelope proteins and specific cellular receptors. The antibodies were conjugated to the biotin moiety using streptavidin (Roux et al., Proc. Nat'l Acad. Sci. USA, 86:9079-9083, 1989). Antibodies against major histocompatibility complex class I and class II antigens were used to demonstrate infection of a variety of human cells bearing these surface antigens by ecotropic viruses in vitro (Roux et al., 1989).
[0107] C. Vector Delivery and Cell Transformation Suitable methods of nucleic acid delivery for transforming cells, tissues or organisms for use with the present invention are intended to include virtually any method by which a nucleic acid (e.g., DNA) can be introduced into a cell, tissue or organism, as described herein or as would be known to one of skill in the art. Such methods include direct delivery of DNA, for example, by ex vivo transfection, optionally using Fugene6 (Roche) or Lipofectamine (Invitrogen) (Wilson et al., Science, 244:1344-1346, 1989; Nabel and Baltimore, Nature 326:711-713, 1987), microinjection (Harland and Weintraub, J. Cell Biol., 101:1094-1099, 1985; U.S. Patent No. 5,789,215, which is incorporated herein by reference), by injection (U.S. Patent Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466, and 5,580,859, each of which is incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, which is incorporated herein by reference; Tur-Kaspa et al., Mol. Cell Biol., 6:716-718, 1986; Potter et al., Proc. Nat'l Acad. Sci. USA, 81:7161-7165, 1984); calcium phosphate precipitation (Graham and Van Der Eb, Virology, 52:456-467, 1973; Chen and Okayama, Mol. Cell Biol., 7(8):2745-2752, 1987; Rippe et al., Mol. Cell Biol., 10:689-695, 1990); using DEAE-dextran followed by polyethylene glycol (Gopal, Mol. Cell Biol., 5:1188-1190, 1985); by direct sonic loading (Fechheimer et al., Proc. Nat'l Acad. Sci. USA, 84:8463-8467, 1987); by liposome-mediated transfection (Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190, 1982;Fraley et al., Proc. Nat'l Acad. Sci. USA, 76:3348-3352, 1979;Nicolau et al., Methods Enzymol., 149:157-176, 1987;Wong et al., Gene, 10:87-94, 1980;Kaneda et al., Science, 243:375-378, 1989; Kato et al., J. Biol. Chem., 266:3361-3364, 1991) and by receptor-mediated transfection (Wu and Wu, Biochemistry, 27:887-892, 1988; Wu and Wu, J. Biol. Chem., 262:4429-4432, 1987), each of which is incorporated herein by reference, as well as any combination of such methods.
[0108] V. Cell Culture Pluripotent cells, such as embryonic stem cells, and cells induced to pluripotency or cells to be induced to pluripotency can be cultured according to any method known in the art. As described herein, in some embodiments, pluripotent cells are cultured with an ALK5 inhibitor and one of a MEK or Erk inhibitor, optionally with a GSK3β inhibitor and / or LIF. The culture medium can include any other components of culture medium known in the art. In some embodiments, the culture medium includes basal medium components for cell survival (e.g., vitamins and minerals, optionally under isotonic conditions). An exemplary basal medium is DMEM or a variant thereof, such as DMEM Knockout. The culture can further be supplemented with Knock-out serum replacement supplement (KSP). The culture of the present invention can include one or more carbon sources. In some embodiments, the culture includes L-analyl-L-glutamine. The culture can include serum or can be serum-free.
[0109] In some embodiments, cells are cultured in contact with feeder cells.Exemplary feeder cells include, but are not limited to, fibroblasts, such as mouse embryonic fibroblasts (MEF), or X-ray inactivated CF1 feeder cells.The method of culturing cells on feeder cells is known in the art.
[0110] In some embodiments, the cells are cultured in the absence of feeder cells. The cells can be attached directly to, for example, a solid culture surface (e.g., a culture plate), for example, via a molecular tether. The inventors have found that in cultures of cells undergoing induction of pluripotency, the induction of pluripotency is much more efficient (i.e., more cells acquire pluripotency) when the cells are attached directly to a solid culture surface, compared to the efficiency of cells cultured on feeder cells but otherwise treated the same way. Exemplary molecular tethers include, but are not limited to, matrigel, extracellular matrix (ECM), ECM analogs, laminin, fibronectin, or collagen. However, it will be understood by those skilled in the art that this is a non-limiting list, and that other molecules can also be used to attach cells to a solid surface. Methods for initially attaching a tether to a solid surface are known in the art.
[0111] VI. Uses of Pluripotent Cells The present invention allows further research and development of stem cell technology, including but not limited to preventive or therapeutic applications. For example, in some embodiments, the cells of the present invention (pluripotent cells cultured under the inhibitors of the present invention, or cells derived from such cells and induced to differentiate along a desired cell fate) are introduced into an individual in need thereof, including but not limited to an individual in need of regeneration of an organ, tissue, or cell type. In some embodiments, the cells are first obtained in a biopsy from an individual, induced to pluripotency as described herein, optionally induced to differentiate (e.g., into a specific desired progenitor cell), and then transplanted back into the individual. In some embodiments, the cells are genetically modified before being introduced into the individual.
[0112] In some embodiments, the pluripotent cells generated according to the methods of the invention are then induced to form, for example, hematopoietic (stem / progenitor) cells, neural (stem / progenitor) cells (and optionally more differentiated cells, e.g., subtype-specific neurons, oligodendrocytes, etc.), pancreatic cells (e.g., endocrine precursor cells or pancreatic hormone-expressing cells), hepatic cells, cardiovascular (stem / progenitor) cells (e.g., cardiomyocytes, endothelial cells, smooth muscle cells), retinal cells, etc.
[0113] There are various methods known for inducing differentiation of pluripotent stem cells into desired cell types. A non-exclusive list of recent patent publications that describe methods for inducing differentiation of stem cells into various cell fates is given below: US Patent Application Publication Nos. 2007 / 0281355; 2007 / 0269412; 2007 / 0264709; 2007 / 0259423; 2007 / 0254359; 2007 / 0196919; 2007 / 0172946; 2007 / 0141703; 2007 / 0134215.
[0114] By introducing and optionally targeting the pluripotent cells of the present invention to specific damaged tissue or other tissues that would benefit from pluripotent cells, various diseases can be improved.Examples of diseases caused by tissue damage include, but are not limited to, neurodegenerative diseases, cerebral infarction, occlusive vascular disease, myocardial infarction, heart failure, chronic obstructive pulmonary disease, emphysema, bronchitis, interstitial lung disease, asthma, hepatitis B (liver damage), hepatitis C (liver damage), alcoholic hepatitis (liver damage), cirrhosis (liver damage), liver dysfunction (liver damage), pancreatitis, diabetes mellitus, Crohn's disease, inflammatory bowel disease, IgA glomerulonephritis, glomerulonephritis, kidney dysfunction, bedsore, burn, suture wound, laceration, incision, bite, dermatitis, scar keloid, keloid, diabetic ulcer, arterial ulcer and venous ulcer.
[0115] In some embodiments, transgenic animals (e.g., non-human animals) are produced from pluripotent cells incubated with the inhibitors of the present invention. Such cells can be transgenic cells, knockout strains (e.g., those that contain one or more gene knockouts that introduce selectable markers by site-specific recombination). Pluripotent cells incubated with the inhibitors described herein can be introduced into blastocysts from compatible animals and then introduced into the receptive uterus of the animals, and the resulting offspring can be selected for cells derived from pluripotent cells (e.g., by selectable markers or other phenotypic characteristics such as coat color). Chimeric offspring can be identified and lines that transmit characteristics (e.g., transgenes) from pluripotent cells to offspring can be established. Homozygous animal lines can be established by mating sibling animals.
[0116] The present invention provides for the production of any type of transgenic animal by this method.Exemplary animals include non-human mammals and non-human primates.Exemplary animals include, for example, mice (including SCID mice), rats, dogs, cats, pigs, cows, sheep, goats, monkeys and chimpanzees.
[0117] Culturing cells with the inhibitors of the present invention, thus maintaining the pluripotency of the cells, advantageously allows screening for cell phenotypes, drug responses, and also allows screening libraries of compounds or other agents (e.g., proteins, nucleic acids, or antibodies) for their ability to modulate the phenotype of pluripotent cells or induce desired cellular responses. Library screening can be designed to screen for the ability of library members to affect essentially any desired phenotype. Exemplary phenotypes can include, for example, cell differentiation, apoptosis or other cell death, cell survival, death, or other phenotypes in the presence of additional compounds or drugs of interest, etc.
[0118] The agents in the library can be any small chemical compound or biological entity, such as a protein, sugar, nucleic acid, or lipid. Typically, the test agents are considered to be small chemical molecules and peptides. Although essentially any chemical compound can be used as a potential agent in the assays of the present invention, most often compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large compound libraries by automating the assay steps and supplying the compounds from any convenient source to the assays, which are typically performed in parallel (e.g., in a microtiter format on a microtiter plate in a robotic assay). It will be understood that there are many suppliers of chemical compounds, such as Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland).
[0119] A combinatorial chemical library is a diverse collection of chemical compounds created by chemical or biological synthesis by combining several chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide library, is formed by combining a set of chemical building blocks (amino acids) in all possible ways for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized by such combinatorial mixing of chemical building blocks.
[0120] The creation and screening of combinatorial chemical libraries is well known to those skilled in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, for example, U.S. Patent No. 5,010,175; Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991); and Houghton et al., Nature 354:84-88 (1991)). Other chemistries can also be used to create chemical diversity libraries. Such chemistries include peptoids (e.g., PCT Publication No. WO 91 / 19735), encoded peptides (e.g., PCT Publication No. WO 93 / 20242), random bio-oligomers (e.g., PCT Publication No. WO 92 / 00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), hydantoins, diversomers such as benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), non-peptide peptidomimetics with a glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:6568 (1992)), and the like. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen, et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and / or peptidyl phosphonates (Campbell et al., J. Org. Chem.59:658 (1994)), nucleic acid libraries (see Ausubel, Berger, and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT / US96 / 10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (e.g., benzodiazepines, Baum C&EN, Jan 18, p. 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, etc.).
[0121] Equipment for generating combinatorial libraries is commercially available (see, e.g., 357MPS, 390MPS from Advanced Chem Tech (Louisville, KY), Symphony from Rainin (Woburn, MA), 433A from Applied Biosystems (Foster City, CA), 9050 Plus from Millipore (Bedford, MA)). Additionally, many combinatorial libraries themselves are commercially available (see, e.g., ComGenex (Princeton, NJ), Tripos, Inc. (St. Louis, MO), 3D Pharmaceuticals (Exton, PA), Martek Biosciences (Columbia, MD), etc.). EXAMPLES
[0122] overview: Here we report the successful establishment of novel rat iPSCs (riPSCs) that can be homogeneously maintained by LIF and a cocktail of ALK5, GSK3, and MEK inhibitors. riPSCs share characteristics with mouse ESCs, and most importantly, can contribute significantly to chimeras. We also generated novel human iPSCs (hiPSCs) that have "mouse ESC-like" characteristics and, surprisingly, can be maintained in culture in the presence of MEK and ALK5 inhibitors. We believe that our experiments provide a framework for reprogramming pluripotent stem cells from rats or other species for which authentic embryonic stem cells are not yet available.
[0123] Example 1 This example demonstrates the generation and maintenance of rat pluripotent cells.
[0124] Generation of novel riPSCs from WB-F344 cells by Oct4 / Klf4 / Sox2 viral transduction and chemical cocktails A diploid rat liver progenitor cell line, WB-F344 (Grisham et al., Proc Soc Exp Biol Med 204, 270-279 (1993)), was retrovirally transduced with Oct4, Sox2, and Klf4 and then split onto MEF feeder cells in conventional mESC medium. Compact alkaline phosphatase (ALP)-positive ESC-like colonies were observed 10 days after transduction (efficiency of about 0.4%) (Figure 1A). However, when the ESC-like colonies were picked and subcultured in the same medium, they rapidly differentiated and lost ESC morphology (Figure 1B), suggesting that conventional mESC medium conditions were not sufficient to maintain the pluripotency of riPSCs. Based on the idea that small molecules can inhibit important differentiation induction pathways, the present inventors and others have previously identified and used small molecules to support mESC self-renewal in a more robust manner (Schugar et al., Gene Ther 15, 126-135 (2008); Xu et al., Nat Biotechnol 20, 1261-1264 (2002)). Based on such chemical strategies and the differences in signaling to maintain the self-renewal of mESCs and EpiSCs / hESCs, the present inventors selected MEK inhibitor PD0325901, ALK5 (the main type I receptor of TGFβ signaling) inhibitor A-83-01, GSK3β inhibitor CHIR99021, and FGFR inhibitor PD173074 to investigate the effects of different small molecule combinations on maintaining the pluripotency of riPSCs. Using a combination of 0.5 μM PD0325901 and 3 μM CHIR99021, riPSCs can be maintained in culture for short periods but show extensive spontaneous differentiation (Figure 1C). Cells grown under these conditions proliferated slowly after serial passages, and cultures deteriorated due to proliferation of differentiated cells. Recent studies have demonstrated that PD0325901 in combination with CHIR99021 and the FGFR inhibitor PD173074 can maintain the pluripotency of mESCs in a LIF-independent manner (Ying et al., Cell 115, 281-292 (2003)).However, similar to the combination of PD0325901 and CHIR99021, the inclusion of PD173074 (0.1 μM) in the medium showed no additional benefit. Because Activin A / Nodal signaling is important for maintaining the undifferentiated state of hESCs and EpiSCs but is dispensable for mESC self-renewal, we next investigated whether the combination of PD0325901, CHIR99021 and the TGF-β inhibitor A-83-01 could suppress differentiation and promote self-renewal of riPSCs. Interestingly, the combination of 0.5 μM PD0325901, 3 μM CHIR99021 and 0.5 μM A-83-01 caused riPSCs to grow as a more homogenous population and spontaneous differentiation was substantially inhibited (Figure 1D). Under such conditions, clonal expansion efficiency was also significantly increased compared to the combination of PD0325901 and CHIR99021 (Figure 5). Furthermore, although LIF itself was not sufficient to sustain riPSC self-renewal, only very small ALP-positive colonies were observed in the absence of LIF, and they could not be maintained for long periods (Figure 5). Moreover, a unique chemical inhibitor cocktail was required for long-term self-renewal of riPSCs. riPSCs were cultured in the presence of LIF, PD0325901, A-83-01, and CHIR99021 for more than 30 passages without obvious differentiation or reduced proliferation, but lost ESC morphology and differentiated within one passage after the chemical inhibitors were removed from the medium. Under these conditions, riPSCs resembled conventional mESCs in forming typical dome-shaped colonies in culture (Figure 1E). Immunocytochemistry revealed that riPSCs expressed typical mESC markers such as Oct4 (Fig. 1F), Sox2 (Fig. 1G), SSEA-1 (Fig. 1H, green), and Nanog (Fig. 1H, red), but were negative for hESC markers such as SSEA3, SSEA4, and TRA-1-81. RT-PCR analysis of the four clonal riPSC lines using rat gene primers confirmed the expression of endogenous rat Oct4, Sox2, Nanog, Klf4, Rex-1, TDGF2, FGF4, and Eras (Fig. 1I).Using specific primers for the transgenes, RT-PCR analysis revealed that the transduced mouse Oct4, Sox2, and Klf4 genes were largely silenced (Figure 1I). Analysis of the methylation status of the rat Oct4 promoter showed differential methylation between riPSCs and WB-F344 cells. riPSC clones showed an almost complete demethylation pattern, distinct from that of the parental WB-F344 cells (Figure 1J). Notably, riPSCs share molecular features with mESCs, in particular expressing Rex-1 and ALP, markers of ESCs and early epiblast that are absent in postimplantation stage epiblasts and EpiSCs.
[0125] riPSCs are pluripotent stem cells in vitro and in vivo To examine the developmental potential of riPSCs, in vitro differentiation assays were performed. Immunostaining showed that riPSCs could differentiate into endodermal (albumin and Pdx1) (Figure 2A, 2B), neuroectodermal (βIII-tubulin, Tuj1) (Figure 2C) and mesodermal (brachyury) (Figure 2D) derivatives under standard embryoid body differentiation methods. Next, we examined the in vivo developmental potential of riPSCs. After transplantation into severe combined immunodeficient (SCID) mice, riPSCs formed teratomas composed of all three germ layers, including neuroepithelial-like structures (ectoderm), airway epithelium (endoderm), cartilage-like structures (mesoderm) and smooth muscle (mesoderm) (Figure 2E-2H). Most notably, after injection into Brown-Norway rat (black hair) blastocysts (n=18), three rats were born, all of which showed gross coat color chimerism (Figure 2I). However, germline transmission has not yet been detected. Collectively, the above results defined our riPSCs, which are distinct from rat EpiSCs, as pluripotent mESC-like rat stem cell lines.
[0126] Example 2 This example demonstrates a culture medium for inducing and maintaining human pluripotent cells in a state similar to mouse embryonic stem cells.
[0127] In contrast to mESCs, bFGF and TGFβ / Activin / Nodal signaling are essential to maintain the self-renewal of conventional hESCs and EpiSCs. Inhibition of either TGFβ / Activin / Nodal or FGFR signaling leads to dramatic and rapid differentiation of hESCs and EpiSCs under conventional hESC culture conditions. Recently, human induced pluripotent stem cells (hiPSCs) have been generated from fibroblasts by expressing either Oct4, Sox2, c-Myc and Klf4 or Oct4, Sox2, Nanog and Lin28 under bFGF culture conditions (Dimos et al., Science 321, 1218-1221 (2008);Lowry et al., Proc Natl Acad Sci USA 105, 2883-2888 (2008);Nakagawa et al., Nat Biotechnol 26, 101-106 (2008);Takahashi et al, Cell 131, 861-872 (2007);Yu et al., Science 318, 1917-1920 (2007)). Such hiPSCs resemble conventional hESCs and EpiSCs in signaling requirements and cell morphology for self-renewal. Based on the rat studies, we explored whether we could capture and maintain a mESC-like diversity state for human pluripotent stem cells. Remarkably, we found that viral expression of Oct4, Sox2, Nanog, and Lin28 in mESC medium containing hLIF resulted in the generation of hiPSCs with similar timing and efficiency (Figure 3A, 1x10 on average) as under conventional conditions (Yu et al., Science 318, 1917-1920 (2007)). 5We found that we could effectively generate hiPSCs from IMR90 human fibroblasts (15–20 iPS cell colonies from 1 transduced cell), and then select and expand them by adding a compound cocktail of ALK5, GSK3 and MEK inhibitors. Such hiPSCs self-renew homogeneously for long periods (>20 passages) under hLIF and the compound cocktail of PD0325901, A-83-01 and CHIR99021 (Figure 3B). In contrast to conventional hESCs, these hiPSCs formed ALP-positive dome-shaped colonies resembling mESCs (Figure 3C) and were resistant to MEK and ALK5 inhibitors, whereas the conventional hESC line H1 rapidly differentiated under the same conditions. These hiPSCs homogeneously express typical pluripotency markers, such as Oct4, Sox2, Nanog, TRA-1-81, SSEA3 and SSEA-4 (Figure 3D–3I). RT-PCR analysis of four clonal hiPSC lines under such conditions confirmed the expression of endogenous human Oct4, Sox2, Nanog, Rex-1, TDGF2 and FGF4 (Figure 3J). Using specific primers for the transgenes, RT-PCR analysis revealed that the transduced Oct4, Sox2 and Nanog genes were largely silenced (Figure 3J). Moreover, these hiPSCs showed DNA methylation patterns on the Oct4 promoter similar to those of H1 human ESCs and distinct from those of the parental IMR90 fibroblasts (Figure 3K). Similar to riPSCs, the inhibitor cocktail was required to maintain the dome-shaped colony morphology and long-term in vitro self-renewal of hiPSCs. Removal of the inhibitor cocktail caused the cells to lose colony passage within one passage. Removal of hLIF from the medium had no immediate / dramatic effect on the cells. However, hLIF appears to be useful for long-term culture of hiPSCs. When cultured in medium containing chemical inhibitors but not hLIF, hiPSC cultures gradually deteriorated and could not be homogeneously passaged for more than 10 passages. Nevertheless, the precise signaling mechanisms underlying the self-renewal of the novel hiPSCs described above remain to be determined.
[0128] Importantly, immunocytochemistry confirmed that the novel hiPSCs described above could differentiate into endodermal (albumin) (Figure 4A), neuroectodermal (βIII-tubulin, Tuj1) (Figure 4B), and mesodermal (brachyury) (Figure 4C) derivatives in vitro. Furthermore, after transplantation into SCID mice, the hiPSCs formed teratomas composed of all three germ layers, including neuroepithelial-like structures (ectoderm) (Figure 4D), epithelial tubular structures (endoderm) (Figure 4D), and cartilage-like structures (mesoderm) (Figure 4E). Taken together, the above results suggested that mESC-like human pluripotent cells could be captured and maintained for a long period of time.
[0129] Consideration Embryonic stem cells have been established from mice since 1981 (Martin, GR, Proc Natl Acad Sci USA 78, 7634-7638 (1981)), but attempts to obtain their counterparts from other animals, such as rats, have not been entirely successful (Demers et al., Cloning Stem Cells 9, 512-522 (2007);Ruhnke et al., Stem Cells 21, 428-436 (2003), 2003;Schulze et al., Methods Mol Biol 329, 45-58 (2006);Ueda et al. "Establishment of rat embryonic stem cells and making of chimera rats" PLoS ONE 3, e2800 (2008)). By combining genetic reprogramming with chemical approaches, we were able to generate novel mESC-like rat and human pluripotent stem cells that possess key characteristics of conventional mESCs in terms of colony morphology and culture requirements / signaling responses. Under a unique cocktail of small molecules, our stable riPSCs had the ability to contribute significantly to chimerism in vivo. Rats are more suitable for physiological and behavioral studies and are an excellent model for multigenic human diseases. However, the unavailability of rat stem cells with pluripotency in vivo has hindered the exploitation of this valuable model. Our establishment of rat pluripotent cells and our strategy with the appropriate compound cocktail will pave the way for biomedical researchers to generate gene-targeted rats. Our hiPSCs grow more robustly and appear to represent a novel pluripotent state similar to conventional mESCs and distinct from conventional hESCs.
[0130] Taken together, the above findings highlight the unique advantages of the chemical approach and pinpoint the importance of inhibiting the TGF-β pathway to maintain the mESC-like pluripotent state of rat and human cells. Overall, our work provides a framework for generating pluripotent stem cells by reprogramming or for obtaining early ICM stage ESCs from rats or other species where embryonic stem cells are not yet available.
[0131] Experimental procedure Cell culture and viral transduction: Diploid rat WB-F344 cells, kindly provided by Professor William B. Coleman, University of North Carolina (Grisham et al., Proc Soc Exp Biol Med 204, 270-279 (1993)), were transduced at passage 7 with pMXs-based retroviruses for mouse Oct4, Klf4, and Sox2 (Addgene) as described (Takahashi, K. and Yamanaka, S., Cell 126, 663-676 (2006)). After 24 hours, 1 × 10 5 Transduced WB-F344 cells were seeded onto X-ray inactivated CF1 MEFs in 100 mm dishes and incubated in mESC growth medium: Knockout™ DMEM, 20% Knockout serum replacement supplement, 1% Glutamax, 1% non-essential amino acids, 1% penicillin / streptomycin, 0.1 mM β-mercaptoethanol and 10 3 U / ml mLIF (Millipore). After 10 days, riPSC colonies were picked and treated with MEK inhibitor PD0325901 (Stemgent, 0.5 μM), ALK5 inhibitor A-83-01 (Tocris Bioscience, 0.5 μM), and GSK3β inhibitor CHIR99021 (Stemgent, 3 μM) for growth on MEF feeder cells in mESC growth medium.
[0132] Human fibroblasts IMR90 (ATCC number CCL-186) were cultured and transduced with pSin-EF2-Puro-based lentiviruses (Addgene) for human Oct4, Sox2, Nanog, and Lin28 as described (Yu et al., Science 318, 1917-1920 (2007)). After 24 hours, 1 × 10 5 Transduced IMR-90 cells were plated onto X-ray inactivated CF1 MEF feeder cells in 100 mm dishes. After 24 hours, the medium was replaced with 10 3 The mESC medium was changed to one supplemented with 100 U / ml hLIF (Millipore). After 3 weeks, hiPSC colonies were observed and picked at 4 weeks post-infection for growth on feeder cells in the same medium containing MEK inhibitor PD0325901 (0.5 μM), ALK5 inhibitor A-83-01 (0.25 μM), and GSK3β inhibitor CHIR99021 (3 μM).
[0133] Blastocyst injection: Blastocysts were collected from the uterus of Brown-Norway (BN) females 4.5 days post-coitum. Blastocysts were placed in a drop of HEPES under mineral oil. Eight to fifteen riPSCs were injected into the blastocyst cavity using a microinjection pipette. After injection, blastocysts were transferred to pseudopregnant recipient females. All animal procedures were performed in accordance with the National Institute of Health guidelines.
[0134] Supplementary Data Supplementary Data includes Supplementary Experimental Procedures, one Table, and one Figure.
[0135] Supplementary Experimental Procedures Differentiation of iPSCs in vitro: In vitro differentiation of riPSCs or hiPSCs was performed by standard embryoid body differentiation methods. riPSCs or hiPSCs were dissociated with 0.05% trypsin-EDTA and cultured in ultra-low attachment 100 mm dishes in DMEM medium supplemented with 10% FBS to form embryoid bodies (EBs). Medium was changed every other day. After 1 week, EBs were collected and transferred to Matrigel-coated 6-well plates in DMEM medium containing 10% FBS. After 3–7 days, cells were fixed for immunocytochemistry analysis. All cell culture products were obtained from Invitrogen / Gibco BRL unless otherwise noted.
[0136] Cytochemistry and immunofluorescence assays: Alkaline phosphatase staining was performed using the Alkaline Phosphatase Detection Kit (Millipore) according to the manufacturer's protocol. For immunofluorescence assays, cells were fixed in 4% paraformaldehyde for 10 min and washed three times with PBS containing 0.1% Triton X-100 (Sigma-Aldrich). Fixed cells were then incubated in blocking buffer, 0.1% Triton X-100 and 10% normal donkey serum (Jackson ImmunoResearch Laboratories Inc) in PBS (Invitrogen / Gibco BRL) for 30 min at room temperature (RT). Cells were then incubated with primary antibodies in blocking buffer overnight at 4°C. The next day, cells were washed with PBS and incubated with secondary antibodies in PBS containing 0.1% Triton X-100 for 1 h at room temperature. The primary antibodies used were mouse anti-Oct4 (1:250) (Santa Cruz Biotechnology), rabbit anti-Sox2 (1:2000) (Chemicon), mouse anti-SSEA1 (1:250) (Santa Cruz Biotechnology), rabbit anti-Nanog (1:500) (Abcam), rat anti-SSEA3 (1:1000) (Chemicon), mouse anti-SSEA4 (1:1000) (Chemicon), mouse anti-TRA-1-81 (1:1000) (Chemicon), rabbit anti-Pdx1 (1:1500) (gift from Dr. C. Wright, Vanderbilt University, TN), mouse anti-βIII-tubulin (Tuj1) (1:1000) (Covance Research Products), and rabbit anti-albumin (1:1000) (DAKO). Secondary antibodies were Alexa Fluor 486 / 555 donkey anti-mouse, anti-rat, anti-goat or anti-rabbit IgG (1:500) (Invitrogen). Nuclei were visualized by DAPI (Sigma-Aldrich) staining. Images were captured using a Nikon Eclipse TE2000-U microscope.
[0137] RT-PCR analysis: RNA was extracted from riPSCs and hiPSCs using the RNeasy Plus Mini Kit in conjunction with QIAshredder (Qiagene). Reverse transcription was performed with 1 μg of RNA using the iScript™ cDNA Synthesis Kit (BioRad). Amplification of specific genes was performed using the primers shown in Table 1. PCR conditions were 95°C for 5 min, 94°C for 30 s, annealing temperature for 30 s, and 72°C for 30 s, for 25–35 cycles, followed by 72°C for 10 min. For Oct4 promoter methylation studies using the bisulfite sequencing method, DNA was isolated from WB-F344 cells, riPSCs, IMR90, and hiPSCs using the Non Organic DNA Isolation Kit (Millipore). The DNA was then treated with the EZ DNA Methylation-Gold Kit (Zymo Research Corp., Orange, CA). The treated DNA was then used as a template to amplify the sequences of interest. The primers used for amplifying the Oct4 promoter fragment are shown in Table 1. The resulting fragment was cloned and sequenced using the TOPO TA Cloning Kit for sequencing (Invitrogen).
[0138] Teratoma formation: Serially passaged riPSCs or hiPSCs were harvested using 0.05% trypsin-EDTA. Three to five million cells were injected under the kidney capsule of SCID mice (n=3). After 4-5 weeks, all mice developed teratomas. The teratomas were removed and analyzed histologically.
[0139] (Table 1) List of PCR primer information TIFF2024098047000002.tif242166
[0140] Example 3: Derivation of rat embryonic stem cells To derive rat ES cells from blastocysts, zona-removed rat blastocysts (E4.5) were seeded on X-ray inactivated CF1 feeder cells with Knock-out DMEM medium supplemented with 20% Knock-out serum replacement supplement (KSR), 1% non-essential amino acids, 1000U / ml mouse LIF, 1% Glutmax, 3μM CHIR99021, 0.5μM PD0325901, 0.25μM A-83-01 (or 2μM SB431542). After 3–5 days, ICM-derived cell clusters were dissociated by Accutase and transferred onto new feeders. Colonies with typical ES cell morphology were picked up, dissociated by Accutase, and then seeded onto new feeders. The established rat ES cells were cultured in the above medium and passaged (1:6) approximately every 3 days. Both rat ES cells and riPSCs require the presence of LIF and a cocktail of inhibitors (CHIR99021, PD0325901, A-83-01) for long-term self-renewal. Rat ES cells and riPSCs express pluripotency markers of mouse ES cells, such as Oct4, Sox2, Nanog, and SSEA-1, but not markers expressed by conventionally cultured human ES cells, such as SSEA-3, SSEA-4, TRA-1-61, and TRA-1-81. Both rat ES cells and riPSCs express ICM markers Rex-1 and ALP, which are not expressed in mouse EpiSCs.
[0141] Example 4: Derivation of human and monkey embryonic stem cells To convert human and monkey ES cells to a mouse ES cell-like (early ICM) pluripotent state, human ES cells (Hues9) and monkey ES cells (R366.4) were cultured in DMEM / F-12 medium supplemented with 20% Knock-out serum replacement supplement (KSR), 1% non-essential amino acids, 1% Glutmax, and 10ng / ml bFGF. When the cells reached 50% confluence, the medium was switched to Advance DMEM / F-12, 1xN2, 1xB27, 1% Glutmax, 50μg / ml BSA medium supplemented with 2μM lysine-specific demethylase 1 inhibitor (parnate). After 3 days, the cells were cultured in the same medium containing 10μg / ml human LiF, 3μM CHIR99021, 0.5μM PD0325901, and 2μM SB431542 but without parnate. Despite extensive differentiation, compact mouse ES cell-like colonies became visible after approximately one week of treatment. The transformed human / monkey ES cells were cultured in the above medium and passaged (1:6) approximately every 4-5 days. The cells express pluripotency markers such as Oct4, Sox2, Nanog, SSEA-3, SSEA-4, TRA-1-61, and TRA-1-81, as well as ICM markers Rex-1 and ALP.
[0142] Example 5: Conversion of epiblast stem cells into embryonic stem cells by small molecules Classical mouse embryonic stem cells (ESCs) are derived from and correspond to pluripotent cells of the inner cell mass (ICM) of the preimplantation blastocyst. They can self-renew indefinitely, have the capacity to give rise to all cell types in vitro, and most importantly, when transferred back to the blastocyst, have the capacity to contribute to the whole animal, including the germ line, in vivo. Recently, a different type of pluripotent cell, called epiblast stem cells (EpiSCs), has been derived from the epiblast at the postimplantation stage (Brons et al., Nature 448, 191-195, 2007; Tesar et al., Nature 448, 196-199, 2007). Although EpiSCs can self-renew for long periods and appear to be pluripotent in vitro and in vivo in teratoma assays, in contrast to mESCs, they do not have the ability to integrate into the ICM and contribute to chimerism, confirming that EpiSCs originate from and represent a more advanced / later developmental stage of pluripotency than ICM-derived ESCs and suggesting that they cannot be "reprogrammed" back to ICM-stage pluripotent cells, even in an in vivo environment. Conventional human ESCs, although derived using blastocysts, appear to correspond very closely to EpiSCs in many features, including some gene expression, colony morphology (i.e. flattened colonies), and signaling responses during self-renewal and differentiation. EpiSCs / hESCs also differ in many other functional and mechanistic ways from mESCs (which have a more compact and dome-like colony morphology).For example, mESCs self-renew under leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP) (Ying et al., Cell 115, 281-292, 2003) or under MEK and / or FGFR inhibition (Ying et al., Nature 453, 519-523, 2008), whereas EpiSCs / hESCs appear to depend on MAPK, FGF, and TGFβ / Activin / Nodal pathway activity for self-renewal and rapidly differentiate when treated with MEK, FGFR, and / or ALK4 / 5 / 7 inhibitors (Brons et al., Nature 448, 191-195, 2007;Li et al., Differentiation 75, 299-307, 2007;Peerani et al., EMBO J 26, 4744-4755, 2007;Tesar et al., Nature 448, 196-199, 2007). Under defined differentiation conditions, mESCs differentiate into mesodermal lineages in response to BMP treatment, whereas EpiSCs / hESCs give rise to trophoblast or primitive endoderm cells (Brons et al., Nature 448, 191-195, 2007;D'Amour et al., Nat Biotechnol 23, 1534-1541, 2005;Xu et al., Nat Biotechnol 20, 1261-1264, 2002). These observations strongly support the notion that EpiSCs and hESCs are essentially similar, and since mESCs and EpiSC / hESCs represent two distinct diversity states, an mESC-like state representing the ICM of the preimplantation blastocyst and an EpiSC-like state representing the postimplantation epiblast, raise the attractive hypothesis of whether the epiblast state (including conventional hESCs) can be converted back to the ICM state. Because there is a clear difference in the ability to contribute to chimerism from mESCs or mEpiSCs (which would be a definitive confirmation of the functional conversion of EpiSCs to mESCs), the mouse system represents an ideal platform to study such an intriguing process, perhaps providing the basis for generating a new type of ICM / mESC-like human pluripotent cells from conventional hESCs.
[0143] EpiSCs express master pluripotency genes, including Oct4, Sox2, and Nanog. Overexpression of Oct4, Sox2, and Klf4 has been shown to induce reprogramming of mouse somatic cells to become germline-competent pluripotent cells (Nakagawa et al., Nat Biotechnol 26, 101-106, 2008). It has also been shown that germline stem cells expressing a low number of pluripotency genes (e.g., lacking Nanog expression) can be transformed into mESC-like cells in culture (Chambers et al., Nature 450, 1230-1234, 2007; Kanatsu-Shinohara et al., Cell 119, 1001-1012, 2004). Furthermore, a non-pluripotent cell type (called FAB-SC) has recently been derived from blastocysts and shown to generate pluripotent mESC-like cells solely under LIF and BMP conditions (Chou et al., Cell 135, 449-461, 2008). Moreover, recent studies have suggested that subpopulations of cells within mESC colonies exhibit dynamic expression of several key transcription factors (e.g., Nanog, Rex1, and Stella), which causes them to constantly fluctuate between different states (e.g., between ESC-like and epiblast-like phenotypes) (Chambers et al., Nature 450, 1230-1234, 2007; Hayashi et al., Cell Stem Cell 3, 391-401, 2008; Singh et al., Stem Cells 25, 2534-2542, 2007; Toyooka et al., Development 135, 909-918, 2008). These studies raise the possibility that EpiSCs, which exist in a less “stable” pluripotent state than ICM-mESCs, may have the ability to “spontaneously” transition backwards to an mESC state under culture fluctuations in vitro.To test this hypothesis, we trypsinized EpiSCs into single cells and plated them under mESC self-renewal conditions, based on the idea that under conditions that promote mESC self-renewal but induce EpiSC differentiation, “transformed” mESC-like cells within EpiSC colonies would be captured / selected and expanded. We found that when cultured with feeder cells under conventional mESC growth conditions, supplemented with LIF, EpiSCs differentiated (e.g., cell spreading / migration outside the colony) at passage 1, and colonies could not be identified for several passages (Figure 6A). Given that “spontaneous” conversion of EpiSCs to mESCs may be highly inefficient, stronger and more stringent differential self-renewal-promoting and differentiation-inducing conditions may be required to select / capture and expand those “rare” transformed mESC-like cells from EpiSCs (e.g., to achieve clearer phenotypic discrimination and minimize overgrowth of differentiated EpiSCs). Based on the differential signaling responses (self-renewal vs. differentiation) between mESCs and EpiSCs in the context of FGF and MAPK signaling pathways, as well as the observation that inhibition of MEK-ERK signaling promotes reprogramming of cells to a more primitive state (Chen et al., Proc Natl Acad Sci USA 104, 10482-10487, 2007; Shi et al., Cell Stem Cell 2, 525-528, 2008; Silva et al., PLoS Biol 6, e253, 2008), we next treated EpiSCs with a combination of the FGFR inhibitor PD173074 (0.1 μM) and the MEK inhibitor PD0325901 (0.5 μM) under normal mESC self-renewal conditions. Under these 2PD / LIF conditions, which promote robust clonal growth of mESCs and inhibit the growth of differentiated cells, we observed accelerated differentiation of EpiSCs and reduced growth of the entire cell culture. If cultured continuously in 2PD / LIF medium, the majority of cells died and no mESC-like colonies were identified during serial passaging.Similarly, the addition of CHIR99021 (3 μM) to 2PD / LIF conditions to improve mESC growth / survival did not promote or capture the conversion of EpiSCs to an mESC-like state (Figure 6A). These results suggest that EpiSCs represent a "stable" pluripotent state that does not readily spontaneously convert to an ESC-like state under conditions that promote mESC self-renewal. This is consistent with a more recent study showing that conversion of EpiSCs to an mESC-like state was only achieved by the combined overexpression of Klf4 and the use of chemical inhibitors of MEK and GSK3 (Guo et al., Development 136, 1063-1069, 2009).
[0144] TGFβ / Activin / Nodal activity is dynamically regulated in time and space during mouse embryonic development and is required to control the fate of early progenitor cells in the epiblast during implantation (Mesnard et al., Development 133, 2497-2505, 2006). Induction of EpiSCs requires FGF and TGFβ / Activin / Nodal pathway activity, suggesting that TGFβ / Activin / Nodal provides anti-differentiation signals to EpiSCs (Brons et al., Nature 448, 191-195, 2007;Tesar et al., Nature 448, 196-199, 2007). It has also been reported that E-cadherin is expressed in one-cell embryos, and downregulation of E-cadherin by signaling promotes blastocyst implantation (Li et al., J Biol Chem 277, 46447-46455, 2002). Moreover, TGFβ / activin / Nodal activity also promotes epithelial-mesenchymal transition (EMT) by downregulating E-cadherin during gastrulation (Derynck and Akhurst, Nat Cell Biol 9, 1000-1004, 2007;Gadue et al., Proc Natl Acad Sci USA 103, 16806-16811, 2006;Sirard et al., Genes Dev 12, 107-119, 1998). Based on these studies, we hypothesized that inhibition of TGFβ / Activin / Nodal signaling might promote the process of mesenchymal-epithelial transition (MET) and, consequently, the conversion of EpiSCs to a mESC-like state. A-83-01 is a selective ALK4 / 5 / 7 inhibitor that has no cross-inhibitory effect on BMP receptors (Tojo et al., Cancer Sci 96, 791-800, 2005). Consistent with previous reports, blockade of TGFβ / Activin / Nodal signaling with 0.5 μM A-83-01 induced rapid differentiation of EpiSCs under bFGF-supplemented EpiSC / hESC culture conditions.In sharp contrast, under mESC culture conditions supplemented with LIF, A-83-01 induced the entire population of EpiSCs to form more compact dome-shaped colonies that resembled mESC colony morphology and expressed ALP, a pluripotency marker highly expressed in mESCs but not EpiSCs (Figure 6C). Another widely used specific ALK4 / 5 / 7 inhibitor, SB431542, has a similar effect on EpiSCs. When A-83-01-treated colonies were exposed to 2PD / LIF conditions for selection, more than 50% of the colonies were able to self-renew and maintain ALP activity, suggesting that the cells had acquired some mESC properties. These dome-shaped ALP-positive colonies were further maintained and expanded in mESC growth medium supplemented with inhibitors of ALK5, MEK, FGFR, and GSK3 (referred to as mAMFGi conditions). These cells were able to self-renew for long periods under mAMFGi conditions, had indistinguishable mESC colony morphology (Figure 6D), expressed pluripotency markers such as Oct4, Nanog, and SSEA-1, and restored the ICM marker Rex-1. However, when these cells were lentivirally labeled with constitutively active GFP and aggregated with morulae, the resulting embryos did not produce chimeric animals when transplanted into mice (Figure 7A). These results indicate that inhibition of TGFβ signaling in combination with inhibition of MEK, FGFR, and GSK3 has robust reprogramming activity and can promote partial conversion of EpiSCs to an mESC-like state.
[0145] Histone modifications, such as acetylation and methylation, have been established to play important roles in gene regulation. Stella is a key gene for germline competence of mESCs and has been shown to be transcriptionally silent in EpiSCs and epiblast-like cells within mESCs. Moreover, histone modifications regulate Stella expression in mESCs (Hayashi et al., Cell Stem Cell 3, 391-401, 2008; Tesar et al., Nature 448, 196-199, 2007). We hypothesized that derepression of silenced loci responsible for true in vivo pluripotency would help EpiSCs overcome the epigenetic restriction / threshold to a mESC-like state. We therefore selected the small molecule parnate, which has been shown to increase global H3K4 methylation by inhibiting the histone demethylase LSD1, which specifically demethylates mono- and dimethylated histone H3K4 (Lee et al., Chem Biol 13, 563-567, 2006). Remarkably, after 4 days of 2 μM parnate treatment, up to 70-80% of EpiSCs formed small, compact colonies under mESC growth conditions. Parnate-treated cells were then selected with 2PD / LIF, and approximately 20% of the cells survived this selection as dome-shaped, ALP-positive colonies. These colonies were further expanded in MEK, FGFR and GSK3 inhibitors (referred to as mMGFi conditions) or mAMFGi conditions. Both conditions resulted in stable cell cultures (>80 passages over 8 months) that were morphologically indistinguishable from mESCs (Figure 6E,F). We next examined GFP-labeled Parnate / mMFGi and Parnate / mAMFGi cells in vivo by morula aggregation and implantation of the resulting embryos. Notably, we obtained 7 adult chimeras (out of 9 pups born) from Parnate / mAMFGi cells, as determined by coat color and PCR genotyping for the presence of GFP integration in multiple adult tissues (Figure 7A, B, C).Consistently, widespread GFP-positive cells were observed in multiple tissues (i.e., three germ layers including the gonad) of E13.5 embryos obtained from transplantation of parnate / mMFGi cell aggregated morulae (Fig. 7A,D, 10A). To examine germline contribution from parnate / mAMFGi cells, GFP / SSEA-1 double positive cells were isolated from the gonad by FACS and confirmed by real-time PCR that they expressed the germline markers Blimp1 and Stella (Fig. 7E). These data suggest that parnate / mAMFGi cells converted from EpiSCs restore true in vivo pluripotency. In contrast, GFP-positive cells were found only in the yolk sac in E13.5 embryos recovered from transplantation of parnate / mMFGi cell aggregated morulae (Fig. 7A).
[0146] We further characterized Parnate / mAMFGi cells. Immunocytochemistry confirmed homogeneous expression of pluripotency-associated markers, including Oct4, Nanog, SSEA1, and STELLA, in long-term proliferating Parnate / mAMFGi cells (Figs. 8A, 11A, 12). Semiquantitative RT-PCR analysis also demonstrated reinstatement of gene expression of specific ICM and germline competence markers, including Rex1, Pecam1, Stella, Stra8, Dax1, Fbxo15, Esrrb, and Fgf4, expressed in mESCs but absent in EpiSCs (Fig. 8B). In contrast, transcripts of epiblast- and early germ layer-associated genes, such as Fgf5 and Brachyury(T), were reduced or undetectable in Parnate / mAMFGi cells (Figs. 8B, 9C). Furthermore, in agreement with previous reports, microarray transcriptome analysis demonstrated that converted Parnate / mAMFGi cells were much more similar to mESCs (Pearson correlation value: 0.87), whereas the original EpiSCs were more distant from mESCs (Pearson correlation value: 0.74) (Figure 8C). To further analyze the specific epigenetic changes associated with conversion, we investigated the promoter DNA methylation of Stella and Fgf4, whose expression is closely related to the nature of ICM (Hayashi et al., Cell Stem Cell 3, 391-401, 2008; Imamura et al., BMC Dev Biol 6, 34, 2006), by bisulfite genomic sequencing. We found that the promoter regions of Stella and Fgf4 were largely unmethylated in Parnate / mAMFGi cells and mESCs, but highly methylated in EpiSCs (Figure 8D). To further investigate the epigenetic state of Stella restricted to the mESC-like state, we performed ChIP-QPCR analysis of its promoter region in EpiSCs, transformed Parnate / mAMFGi cells, and mESCs.We found that the H3K4 and H3K27 methylation patterns of Stella in Parnate / mAMFGi cells were similar to those observed in mESCs but distinct from those in EpiSCs, confirming that the epigenetic state of Stella in converted Parnate / mAMFGi cells had switched to an mESC-like state (Figure 8E).
[0147] Parnate / mAMFGi cells were also examined for their in vitro functional properties. They were found to have a similar growth rate to mESCs (Figure 9A). When Parnate / mAMFGi cells were differentiated through embryoid bodies in suspension, they could effectively generate cellular derivatives in the three primary germ layers, including characteristic neuronal cells (βIII-tubulin and MAP2ab positive), beating cardiomyocytes (cardiac troponin and MHC positive), and endodermal cells (Sox17 or albumin positive) as shown by immunocytochemistry (Figure 9B). Because mESCs and EpiSCs / hESCs have different responses to signaling inputs (e.g., growth factors) during self-renewal and differentiation, conditions developed and functioning effectively for mESC differentiation are likely insufficient in many cases to induce the corresponding differentiation of EpiSCs / hESCs. One advantage of converting EpiSCs / hESCs to a mESC-like state is that differentiation conditions can be more easily translated from mESC to EpiSC / hESC research. The differential response to BMP4 treatment provides a functional assay to distinguish mESCs from EpiSCs. Consistent with previous studies (Beddington and Robertson, Development 105, 733-737, 1989; Czyz and Wobus, Differentiation 68, 167-174, 2001; Qi et al., Proc Natl Acad Sci USA 101, 6027-6032, 2004; Winnier et al., Genes Dev 9, 2105-2116, 2009). In a study published in the journal Cell Biology, published in the journal Cell Biology, we found that parnate / mAMFGi cells were induced to express the mesoderm-specific marker gene Brachyury (T) similar to mESCs when treated with BMP4, but did not give rise to trophectoderm (no induction of trophoblast marker Cdx2) or primitive endoderm cells (Gata6) like EpiSCs under the same conditions, suggesting an in vitro differentiation potential / response of parnate / mAMFGi cells similar to mESCs (Figure 9C).To further demonstrate this, we attempted and compared EpiSCs, converted Parnate / mAMFGi cells, and mESCs in a monolayer chemically defined, directed, stepwise cardiac differentiation process. In this multi-step process, in which BMP activity plays an essential role in the early stages of mesoderm differentiation, we found that Parnate / mAMFGi cells differentiated into beating cardiomyocytes as efficiently as mESCs, whereas differentiation of EpiSCs under the same conditions produced few cells expressing appropriate cardiac markers or with a characteristic beating phenotype (Figure 9D), again confirming that Parnate / mAMFGi cells are functionally similar to mESCs. Moreover, single-cell survival assays also demonstrated that Parnate / mAMFGi cells clonally expanded as Oct4-positive colonies as efficiently as mESCs in feeder-free N2 / B27 chemically defined conditions, whereas EpiSCs survived poorly from single cells under the same conditions (Figure 11B). These data further demonstrate that EpiSCs can be functionally converted to an mESC-like state by epigenetic modifications and pharmacological manipulations targeting differential signaling pathways required by mESCs or EpiSCs.
[0148] In parallel with our study, it has been recently reported that EpiSC cells can be converted to an mESC-like state by overexpression of reprogramming genes (i.e., Klf4) in combination with chemical compounds (Guo et al., Development 136, 1063-1069, 2009). In this study, we devised a chemically defined process to convert stable EpiSCs to a developmentally earlier pluripotent state, mESC-like, without any genetic manipulation. Despite studies providing evidence that epiblast-like cells exist within and reciprocally transition between colonies of conventional mESCs (Hayashi et al., Cell Stem Cell 3, 391-401, 2008), that mESCs and EpiSCs share a substantial set of pluripotency transcription factors, including Oct4, Sox2, and Nanog, and that mESCs are more stable in culture, in this study we found that EpiSCs differentiate rapidly under conventional mESC culture conditions and that "spontaneously" converted mESCs could not be easily identified and isolated at the population or clonal level during serial passaging. Notably, we found that blocking the TGFβ pathway with small molecule inhibitors or inhibiting the H3K4 demethylase LSD1 induced a dramatic morphological change of EpiSCs to an mESC-like phenotype, accompanied by some activation of ICM-specific gene expression. However, complete conversion of EpiSCs to a mESC-like state with competence for chimera contribution could only be readily achieved using a combination of inhibitors of LSD1, ALK5, MEK, FGFR, and GSK3. These observations highlight the strong and direct induction of reprogramming of developmentally later stage EpiSCs to ICM stage mESCs through the synergistic action of signaling and direct epigenetic modulation. This also highlights the critical role of TGFβ pathway inhibition in promoting reprogramming and maintaining true pluripotency, further supporting our recent study on the generation of chimerism-competent rat pluripotent cells (Li et al., Cell Stem Cell 4, 16-19, 2009).Overall, our study provides a proof-of-concept demonstration that pluripotency-restricted EpiSCs can be easily converted to an mESC-like state by simultaneously applying strict pharmacological control of signaling pathways and epigenetic targets that distinguish the two pluripotent states without any genetic manipulation, and provides a convenient experimental system to further study the mechanism. Such methods and concepts may also be instrumental in generating new types of mESC-like human pluripotent cells.
[0149] Experimental procedure Cell culture: Mouse EpiSC lines were kindly provided by Dr. Paul Tesar (Case Western Reserve University). EpiSCs (EpiSC-5 line, male) were maintained on irradiated CF1 MEFs in human ESC medium supplemented with 10 ng / ml bFGF as previously described (Tesar et al., Nature 448, 196-199, 2007). EpiSCs were passaged every 3-4 days with 1 mg / ml type IV collagenase (Invitrogen). R1 mESCs were cultured in 20% KSR (Invitrogen), 0.1 mM 2-ME (Sigma-Aldrich), 2 mM L-glutamine (Invitrogen), 0.1 mM NEAA (Invitrogen), and 10% erythrocyte sedimentation medium (100 mM NaCl). 3 mESCs and transformed cells were cultured on irradiated CF1 MEFs using conventional mESC growth medium consisting of Knockout DMEM (Invitrogen) supplemented with 1000 units / ml recombinant mouse leukemia inhibitory factor (LIF) (ESGRO, Millipore). mESCs and transformed cells were passaged every 3 days as single-cell suspensions using 0.05% trypsin / EDTA and cultured on 1 cm 2 1.0×10 per 4 For feeder-free culture, cells were seeded at a density of 100 μg / ml in 1× N2 (Invitrogen), 1× B27 (Invitrogen), 0.1 mM 2-ME, 2 mM L-glutamine, 0.1 mM NEAA, 50 μg / ml BSA fraction V (GIBCO), 10 3Cells are grown on gelatin-coated tissue culture dishes in chemically defined medium consisting of Knockout DMEM supplemented with 10ng / ml LIF and 10ng / ml BMP4 (R&D). For growth curve experiments, cells were cultured under feeder filly conditions in gelatin-coated 12-well plates. Duplicate cell samples were added to each well at 1×10 5 Cells were plated at a density of 100x the normal. For each time point (24 h interval), duplicate wells of cells were trypsinized and counted using a hemocytometer. These counts were averaged and plotted. ALK inhibitor A-83-01, SB431542, MEK inhibitor PD0325901, GSK3 inhibitor CHIR99021, and FGF receptor inhibitor PD173074 were purchased from Stemgent Inc. Parnate was purchased from Sigma (P8511).
[0150] Semi-quantitative RT-PCR and real-time PCR: Total RNA was extracted using RNeasy plus mini kit (Qiagen) and reverse transcribed with iScript cDNA Synthesis Kit (Bio-Rad) using oligo dT primers according to the manufacturer's instructions. PCR products were resolved on (1.5%) agarose gels and visualized by ethidium bromide staining. Images were taken using the Bio-Rad Gel document system. Diluted cDNA was used for each of the duplicate quantitative PCRs on a Bio-Rad real-time PCR detection system using IQ SYBR Green (Bio-Rad). The primers used are listed in Supplemental Table 2.
[0151] Bisulfite sequencing analysis: DNA was isolated from R1 mESC, EpiSC, and parnate / mAMFGi cells using the Non Organic DNA Isolation Kit (Millipore). The DNA was then treated with the EZ DNA Methylation-Gold Kit (Zymo Research Corp., Orange, CA) for bisulfite sequencing. The treated DNA was then used to amplify sequences of interest. Primers used for promoter fragment amplification have been published previously (Hayashi et al., Cell Stem Cell 3, 391-401, 2008; Imamura et al., BMC Dev Biol 6, 34, 2006) and are listed in Supplementary Table 2. The resulting fragments were cloned and sequenced using the TOPO TA Cloning Kit for sequencing (Invitrogen).
[0152] Flow cytometry and cell sorting: Adherent cells were washed twice in PBS and then incubated in Cell Dissociation Buffer (Invitrogen) for 20 min at 37°C. Cells were dissociated and resuspended in PBS + 3% normal goat serum (blocking buffer). Cells were incubated with antibody, anti-SSEA1 (1:50, Santa Cruz), for 40 min at 4°C, followed by incubation with the corresponding secondary antibody, followed by a washing step. Cells were analyzed and sorted using a FACSAria cell sorter and FACSDiva software (BD Biosciences). GFP positivity was determined according to the fluorescence intensity in the GFP channel using a 488 nm laser for excitation. SSEA-1 positivity was determined according to the fluorescence in the red channel.
[0153] In vitro differentiation: Parnate / mAMFGi cells were trypsinized to single cells and cultured in suspension to form embryoid bodies / EBs in DMEM medium supplemented with 10% FBS in low attachment plates (Corning). The medium was refreshed every other day and EBs were grown in suspension for 6 days. EBs were then replated on 0.1% gelatin-coated plates. At different time points (from 3 to 16 days), spontaneous differentiation was examined by immunostaining for representative lineage-specific markers with the indicated antibodies. For directed cardiac differentiation, cells were plated at 2 × 10 4 pieces / cm 2 Cardiac colonies were plated at a density of 100-200 μg / well. 24 hours after plating, cells were switched to chemically defined medium (CDM) [consisting of RPMI1640, 0.5x N2, 1x B27 (without vitamin A), 0.5x Glutamax, 0.55 mM β-mercaptoethanol, and 1x non-essential amino acids] and treated with 3 μM BIO (Calbiochem) and 20 ng / ml BMP-4 (R&D) for 5 days. The medium was then changed to CDM containing 100 ng / ml Dkk-1 and cells were cultured for an additional 5 days. On day 11, cells were briefly trypsinized / detached (0.05% trypsin) and replated in CDM without additional growth factors onto gelatin-coated 6-well plates and cultured for an additional 4-6 days, at which point the majority of cardiac colonies exhibited a beating phenotype.
[0154] Characterization assays: ALP staining was performed using the Alkaline Phosphatase Detection Kit (Chemicon) as described by the manufacturer. Immunocytochemistry was performed using standard protocols. Briefly, cells were fixed in 4% paraformaldehyde (Sigma-Aldrich), washed three times with PBS, and then incubated for 1 h at room temperature in PBS containing 0.3% Triton X-100 (Sigma-Aldrich) and 5% normal donkey serum (Jackson Immuno Research). Cells were then incubated overnight at 4°C with primary antibodies: Albumin (Abcam, AB19188, 1:200); Brachyury (Santa Cruz, C-19, 1:200); Cardiac Troponin t antibody (CT3) (Developmental Studies Hybridoma Bank, 1:700); MAP2ab (Abcam, ab5392, 1:1000); MF20 (Developmental Studies Hybridoma Bank, 1:200); Nanog (Abcam, ab21603, 1:500); Oct4 (Santa Cruz, sc-5279, 1:100); Sox17 (R&D systems, AF1924, 1:300); SSEA1 (Santa Cruz, sc-21702, 1:100); Stella (Millipore, MAB4388, 1:200); Tuj-1 (Covance, MMS-435P, 1:1000). After washing three times with PBS, cells were incubated with appropriate Alexa Fluor-conjugated secondary antibodies (Invitrogen) for 2 h at room temperature. Nuclei were detected by DAPI (Sigma) staining. Images were captured by Zeiss HXP120.
[0155] Chimera formation: Transformed cells were stably marked with GFP using lentivirus and aggregated with 8-cell stage mouse embryos and then implanted into the uterus of 2.5 dpc pseudopregnant CD1 mice.
[0156] Microarray Analysis: For microarray hybridization to investigate global gene expression in mouse ES cells, EpiSC cells, and Parnate / mAMFGi cells, Illumina Sentrix BeadChip Array MouseRef-8 v2 (Illumina, CA, USA) was used. Biotin-16-UTP-labeled cRNA was synthesized from 500 ng of total RNA using the Illumina TotalPrep RNA Amplification Kit (Ambion AMIL 1791, Foster City, CA, USA). Hybridization mixture containing 750 ng of labeled amplified cRNA was prepared using supplied reagents and GE Healthcare streptavidin-Cy3 staining solution according to the Illumina BeadStation 500X System Manual (Illumina, San Diego, CA, USA). Hybridization to Illumina Array MouseRef-8 v2 was performed on a BeadChip Hyb Wheel at 55°C for 18 hours. Arrays were scanned using an Illumina BeadArray Reader. All samples were prepared in two biological replicates. Microarray data processing and analysis were performed with Illumina BeadStudio software. R1-mESC cell microarray data were obtained from GEO DataSets (GSM402334 and GSM402335) of our previous study. All raw data were background subtracted and globally normalized using the rank invariant option. We deposited the microarray data of parnate / mAMFGi and EpiSC in GEO DataSets and obtained accession numbers (GSM402334 and GSM402335 for R1 mouse ES cells; GSE17664 for parnate / mAMFGi and EpiSC).
[0157] Real-time PCR of chromatin immunoprecipitates (ChIP-qPCR): ChIP was performed using the commercially available Magna ChIP™ G kit (catalog no. 17-611, Millipore). 6 Cells were fixed with 1% formaldehyde, lysed, and sonicated to obtain nucleosome-associated DNA fragments of 200–500 bp. The sonicated lysates were immunoprecipitated with anti-trimethylhistone H3 lysine 4 (Millipore, Cat. No. 17-614, 3 μl / reaction) or anti-trimethylhistone H3 lysine 27 (Millipore, Cat. No. 17-622, 4 μg / reaction) that had been pre-reacted with secondary antibodies conjugated to magnetic beads. After 24 h of incubation with each antibody, the immunoprecipitates were collected and the contained DNA fragments were purified by incubation with proteinase K. The DNA fragments were subjected to real-time PCR reactions. Whole cell lysates before incubation with antibodies were used as input. 1 μl of DNA fragments from the whole lysates and immunoprecipitates were subjected to real-time PCR reactions. Immunoprecipitation with normal rabbit IgG was used as a negative control sample, but no detectable background was observed. The primer sequences are listed in Table 2.
[0158] (Table 2) Primers used for PCR TIFF2024098047000003.tif112170
[0159] Example 6: Characterization of pluripotent animal cells that replicate and maintain pluripotency To characterize the newly generated hiPSCs, real-time PCR was used to analyze gene expression of hiPSCs. Human ES cell line Hues9 (hES facility, Harvard University, http: / / mcb.harvard.edu / melton / hues / ) was used as a control. Real-time PCR analysis shows that compared with Hues9 cells, the hiPSCs of the present invention express higher levels of certain genes, such as Gbx2 (5-fold), Dppa3 (2-fold) and Klf4 (2.5-fold). It can be seen that these markers are also highly expressed in mouse ES cells, but not in mouse EpiSCs. The primers used for the real-time PCR assay were: The file is TIFF2024098047000004.tif49159.
[0160] Using Western blot analysis, we also analyzed the expression of E-cadherin in hiPSCs, which is twice as high as that in Hues9 human ES cells.
[0161] The above examples are provided to illustrate the present invention and are not intended to limit the scope of the present invention. Other variations of the present invention will be apparent to those skilled in the art and are encompassed by the claims of this application. All publications, databases, Genbank sequences, patents, and patent applications mentioned herein are incorporated herein by reference.
[0162] Sequence information SEQUENCE LISTING <110> The Scripps Research Institute <120> Generation and Maintenance of Stem Cells <150> US 61 / 138,407 <151> 2008-12-17 <160> 91 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> synthetic GSK3 inhibitor L803, unmyristoylated GSK3beta Inhibitor XIII <220> <221> MOD_RES <222> (10)...(10) <223> phosphoserine <220> <221> MOD_RES <222> (11)...(11) <223> prolinamide <400> 1 Lys Glu Ala Pro Pro Ala Pro Pro Gln Ser Pro 1 5 10 <210> 2 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Oct4 <400> 2 tactgcccgc cccagcg 17 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Oct4 <400> 3 gctgcttggc aatgctagt 19 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Sox2 <400> 4 aaggccgtgc acgccgacga 20 <210> 5 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Sox2 <400> 5 accacaccat gaaggcattc at 22 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Nanog <400> 6 tagccctgat tcttctagca 20 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Nanog <400> 7 tttgctgcaa cggcacataa 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Rex-1 <400> 8 aaatcatgac gaggcaaggc 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Rex-1 <400> 9 tgagttcgct ccaacagtct 20 <210> 10 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Klf4 <400> 10 cagacctgga aagtggtgg 19 <210> 11 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Klf4 <400> 11 acctgtgttg cccgcagcc 19 <210> 12 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat TDGF2 <400> 12 aacaccaaca atattttatg tggcc 25 <210> 13 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat TDGF2 <400> 13 tcatttctag gaaaaggcag atgc 24 <210> 14 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat FGF-4 <400> 14 tgtggtgagc atcttcggag tgg 23 <210> 15 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat FGF-4 <400> 15 ccttcttggt ccgcccgttc tta 23 <210> 16 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat Eras <400> 16 gctgcccctc agccgactgc tact 24 <210> 17 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat Eras <400> 17 cactgccttg tactccggta gctg 24 <210> 18 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat transgenic Oct4 <400> 18 ggggtggacc atcctcta 18 <210> 19 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat transgenic Oct4 <400> 19 cctccgcaga actcgtat 18 <210> 20 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat transgenic Sox2 <400> 20 cccaccgccc tcaaagta 18 <210> 21 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat transgenic Sox2 <400> 21 ggaccatacc atgaaggcgt t 21 <210> 22 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat transgenic Klf4 <400> 22 cccaccgccc tcaaagta 18 <210> 23 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat transgenic Klf4 <400> 23 gctggacgca gtgtcttct 19 <210> 24 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for rat GADPH <400> 24 ccttcattga cctcaactac 20 <210> 25 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for rat GADPH <400> 25 ggaaggccat gccagtgagc 20 <210> 26 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human endogenous Oct4 <400> 26 agtttgtgcc agggtttttg 20 <210> 27 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human endogenous Oct4 <400> 27 acttcacctt ccctccaacc 20 <210> 28 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human endogenous Nanog <400> 28 tttggaagct gctggggaag 20 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human endogenous Nanog <400> 29 gatggggagga ggggaggagga 20 <210> 30 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human endogenous Sox2 <400> 30 caaaaatggc catgcaggtt 20 <210> 31 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human endogenous Sox2 <400> 31 agttgggatc gaacaaaagc tatt 24 <210> 32 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human Rex-1 <400> 32 cagatcctaa acagctcgca gaat 24 <210> 33 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human Rex-1 <400> 33 gcgtacgcaa attaaagtcc aga 23 <210> 34 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human FGF-4 <400> 34 ctacaacgcc tacgagtcct aca 23 <210> 35 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human FGF-4 <400> 35 gttgcaccag aaaagtcaga gttg 24 <210> 36 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human TDGF2 <400> 36 ctgctgcctg aatgggggaa cctgc 25 <210> 37 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human TDGF2 <400> 37 gccacgaggt gctcatccat cacaagg 27 <210> 38 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human transgenic Oct4 <400> 38 cagtgcccga aacccacac 19 <210> 39 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human transgenic Oct4 <400> 39 agaggaactg cttccttcac gaca 24 <210> 40 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human transgenic Sox2 <400> 40 tacctctcc tcccactcca 20 <210> 41 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human transgenic Sox2 <400> 41 agaggaactg cttccttcac gaca 24 <210> 42 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human transgenic Nanog <400> 42 cagaaggcct cagcacctac 20 <210> 43 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human transgenic Nanog <400> 43 agaggaactg cttccttcac gaca 24 <210> 44 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for human GADPH <400> 44 gtggacctga cctgccgtct 20 <210> 45 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for human GADPH <400> 45 ggaggagtgg gtgtcgctgt 20 <210> 46 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing forward primer for rat Oct4 <400> 46 atgggatttt ggaggatttt tag 23 <210> 47 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing reverse primer for rat Oct4 <400> 47 ctcaaaccca aataccccta ctt 23 <210> 48 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing forward primer for from Oct4 <400> 48 ggatgttatt aagatgaaga tagttgg 27 <210> 49 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing reverse primer for from Oct4 <400> 49 cctaaactcc ccttcaaaat ctatt 25 <210> 50 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Blimp1 <400> 50 tcagcctctt ccctaggttg tatc 24 <210> 51 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Blimp1 <400> 51 aatcttaagg atccatcggt tcaac 25 <210> 52 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Brachyury <400> 52 atgccaaaga aagaaacgac 20 <210> 53 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Brachyury <400> 53 agaggctgta gaacatgatt 20 <210> 54 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Cdx2 <400> 54 aggctgagcc atgaggagta 20 <210> 55 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Cdx2 <400> 55 cgaggtccat aattccactc a 21 <210> 56 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Dax1 <400> 56 gtggcagggc agcatcctct acaa 24 <210> 57 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Dax1 <400> 57 caaaagaagc ggtaca 16 <210> 58 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Essrb <400> 58 cgccatcaaa tgcgagtaca tgc 23 <210> 59 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Esrrb <400> 59 gaatcaccat ccaggcactc tg 22 <210> 60 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Fbxo15 / ECAT3 <400> 60 tagattcttg gacttccgtt ca 22 <210> 61 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Fbxo15 / ECAT3 <400> 61 accaaggtca ccgcatccaa 20 <210> 62 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Fgf4 <400> 62 cgtggtgagc atcttcggag tgg 23 <210> 63 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Fgf4 <400> 63 ccttcttggt ccgcccgttc tta 23 <210> 64 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Fgf5 <400> 64 ctgtactgca gagtgggcat cgg 23 <210> 65 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Fgf5 <400> 65 gacttctgcg aggctgcgac agg 23 <210> 66 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for GADPH <400> 66 gtgttcctac ccccaatgtg t 21 <210> 67 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for GADPH <400> 67 attgtcatac caggaaatga gctt 24 <210> 68 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Gata6 <400> 68 accttatggc gtagaaatgc tgagggtg 28 <210> 69 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Gata6 <400> 69 ctgaatactt gaggtcactg ttctcggg 28 <210> 70 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Pecam1 <400> 70 gtcatggcca tggtcgagta 20 <210> 71 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Pecam1 <400> 71 agcaggacag gtccaacaac 20 <210> 72 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Rex-1 <400> 72 tgaaagtgag attagccccg ag 22 <210> 73 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Rex-1 <400> 73 gtcccatccc cttcaatagc ac 22 <210> 74 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Stella <400> 74 gaaactcctc agaagaaa 18 <210> 75 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Stella <400> 75 ctcttgttct ccacaggtac 20 <210> 76 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR forward primer for Stra8 <400> 76 gcaaccaacc cagtgatgat gg 22 <210> 77 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> synthetic RT-PCR reverse primer for Stra8 <400> 77 catctggtcc aacagcctca g 21 <210> 78 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR forward primer for Fgf4 <400> 78 tttaggtttt aagagtgttg gggagaagat 30 <210> 79 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR reverse primer for Fgf4 <400> 79 tacaaaacaa aaacatcaaa cccattctaa 30 <210> 80 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR forward primer for Stella <400> 80 attttgtgat tagggttggt ttagaa 26 <210> 81 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR reverse primer for Stella <400> 81 ccaaaacatc ctcttcatct ttcttct 27 <210> 82 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR forward primer for Stella nest <400> 82 tttttggaat tggttgggat tg 22 <210> 83 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> synthetic bisulfite-sequencing PCR reverse primer for Stella nest <400> 83 cttctaaaaa atttcaaaat ccttcatt 28 <210> 84 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic chromatin immunoprecipitation (ChIP-qPCR) forward primer for Stella <400> 84 gatccagctg gtctgagcta 20 <210> 85 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic chromatin immunoprecipitation (ChIP-qPCR) reverse primer for Stella <400> 85 gtgcagggat cataggagtg 20 <210> 86 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Dppa3 <400> 86 caacctacat cccagggtct 20 <210> 87 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Dppa3 <400> 87 tcaacgtctc ggaggagatt 20 <210> 88 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Gbx2 <400> 88 aaaggcttcc tggccaaag 19 <210> 89 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Gbx2 <400> 89 ttgactcgtc tttcccttgc 20 <210> 90 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Klf4 <400> 90 agcctaaatg atggtgcttg gt 22 <210> 91 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> synthetic real-time PCR primer Klf4 <400> 91 ttgaaaactt tggcttcctt gtt 23
Claims
1. 1. A method of culturing pluripotent cells for at least one cell division, comprising: A sufficient amount of the cells was added to maintain pluripotency and to allow at least one cell division. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor; and c. Adequate nutrients for an adequate period of time Culturing the pluripotent animal cells in the presence of The method comprising:
2. The method of claim 1, wherein the culturing step further comprises culturing the cells in the presence of an amount of a GSK3β inhibitor.
3. 3. The method of claim 2, wherein the GSK3β inhibitor is CHIR99021.
4. The method of claim 1, wherein the culturing step further comprises culturing the cells in the presence of a certain amount of leukemia inhibitory factor (LIF).
5. 2. The method of claim 1, wherein the second compound is a MEK inhibitor.
6. 6. The method of claim 5, wherein the MEK inhibitor is PD0325901.
7. 2. The method of claim 1, wherein the second compound is an Erk inhibitor.
8. The method of claim 1, wherein the culturing step is carried out in the presence of additional LIF.
9. 2. The method of claim 1, wherein the ALK5 inhibitor is A-83-01.
10. The method of claim 1, wherein the ALK5 inhibitor is SB431542.
11. The method of claim 1, wherein the pluripotent cells are cultured for at least five cell divisions while maintaining the pluripotency of the cells.
12. 2. The method of claim 1, further comprising the step of introducing a heterologous nucleic acid into the pluripotent cell and culturing the resulting cell to allow at least one additional cell division while maintaining pluripotency.
13. 13. The method of claim 12, wherein the heterologous nucleic acid is introduced into an animal cell, which is then induced to be pluripotent, and which is then subjected to a culture step.
14. The method of claim 1, wherein the cell is a rat cell or a human cell.
15. 2. The method of claim 1, wherein the cell is a primate, ovine, bovine, feline, canine, or porcine cell.
16. The method of claim 1, wherein the pluripotent cells are embryonic stem cells.
17. The method of claim 1, wherein the pluripotent cells are induced pluripotent stem cells.
18. 2. The method of claim 1, further comprising the steps of introducing the pluripotent cells into a blastocyst derived from the same animal species as the cells, and introducing the blastocyst into the uterus of an animal of the same species, wherein the cells are non-human animal cells.
19. 20. The method of claim 18, wherein chimeric progeny of the animal are selected based on the presence of nucleic acid derived from the pluripotent cell.
20. A sufficient amount of the cells was added to maintain pluripotency and to allow at least one cell division. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. A culture of pluripotent mammalian cells comprising:
21. The culture of claim 20, further comprising leukemia inhibitory factor (LIF).
22. The culture of claim 20, further comprising an amount of a GSK3β inhibitor.
23. The culture of claim 22, wherein the GSK3β inhibitor is CHIR99021.
24. The culture of claim 20, wherein the second compound is a MEK inhibitor.
25. The culture of claim 24, wherein the MEK inhibitor is PD0325901.
26. The culture of claim 20, wherein the second compound is an Erk inhibitor.
27. The culture of claim 20, wherein the ALK5 inhibitor is A-83-01.
28. The culture of claim 20, wherein the ALK5 inhibitor is SB431542.
29. The culture of claim 20, wherein the cells are human or rat cells.
30. 21. The culture of claim 20, wherein the cells are embryonic stem cells.
31. 1. A cell culture medium comprising: A sufficient amount of the pluripotent cell is added to the medium so that the pluripotent cell can undergo at least one cell division while maintaining the pluripotency of the cell when cultured in the medium. a. ALK5 inhibitors, and b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, and an FGF receptor inhibitor. The cell culture medium comprising:
32. 32. The medium of claim 31, further comprising leukemia inhibitory factor (LIF).
33. The medium of claim 31, further comprising an amount of a GSK3β inhibitor.
34. The medium of claim 33, wherein the GSK3β inhibitor is CHIR99021.
35. 32. The medium of claim 31 , wherein the second compound is a MEK inhibitor.
36. 36. The medium of claim 35, wherein the MEK inhibitor is PD0325901.
37. 32. The medium of claim 31 , wherein the second compound is an Erk inhibitor.
38. 32. The medium of claim 31 , wherein the ALK5 inhibitor is A-83-01.
39. The medium of claim 31, wherein the ALK5 inhibitor is SB431542.
40. 32. The medium of claim 31, wherein the medium is in a prepackaged, sealed container.
41. (1) in the presence of leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP), or (2) under inhibition of the TGFβ and activin signaling pathways, under inhibition of the MAPK signaling pathway, and optionally under inhibition of the FGF pathway; 1. An isolated pluripotent animal cell which replicates and maintains pluripotency, comprising: However, the isolated pluripotent animal cell is not a mouse embryonic stem cell (mESC).
42. 42. The isolated cell of claim 41, which is a human cell.
43. 43. The isolated cell of claim 42, which is a human embryonic stem cell.
44. 42. The isolated cell of claim 41, which is a rat cell.
45. 45. The isolated cell of claim 44, which is a rat embryonic stem cell.
46. The isolated cell of claim 41, which maintains pluripotency under inhibition of ALK5 and MEK.
47. 42. The isolated pluripotent animal cell of claim 41, which expresses higher levels of E-cadherin as compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells.
48. 48. The isolated pluripotent animal cell of claim 47, which expresses a two-fold higher level of E-cadherin compared to conventionally cultured hESCs, EpiSCs, and human induced pluripotent cells.
49. The isolated pluripotent animal cell of claim 41, which expresses higher levels of markers including Gbx2, Dppa3, Klf4, and Rex1 compared to conventionally cultured hESCs, epiblast stem cells, and human induced pluripotent cells.
50. a. ALK5 inhibitors; b. a second compound selected from one or more of a MEK inhibitor, an Erk inhibitor, a p38 inhibitor, a GSK3 inhibitor, and an FGF receptor inhibitor.
42. The isolated cell of claim 41 , wherein the cell is cultured in the presence of
51. 1. A method for enhancing the pluripotency of a partially pluripotent mammalian cell to a more fully pluripotent cell, comprising: (a) contacting a defective pluripotent cell with an epigenetic modifier selected from a histone deacetylase inhibitor, an inhibitor of histone H3K4 demethylation, or an activator of H3K4 methylation; (b) after step (a), culturing the cells with two or more of: (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, in the absence of epigenetic modifiers, thereby generating cells that are more fully pluripotent as compared to said incompletely pluripotent mammalian cells. The method comprising:
52. (c) culturing the defective pluripotent mammalian cells after step (b) with (i) an ALK5 inhibitor, (ii) a MEK inhibitor, an Erk inhibitor, or a p38 inhibitor, and (iii) an FGF receptor inhibitor, and (iv) a GSK3 inhibitor.
52. The method of claim 51, further comprising:
53. The method of claim 51 or 52, wherein the culturing steps (a) and / or (b) and / or (c) further comprise culturing the defective pluripotent mammalian cells in the presence of leukemia inhibitory factor (LIF).
54. The method of claim 51, wherein the defective pluripotent cells are epiblast stem cells.
55. The method of claim 51, wherein the incompletely pluripotent cells do not express at least one marker selected from the group consisting of Oct4, Nanog, and REX-1, and the more fully pluripotent cells express one or more or all of said markers.
56. 52. The method of claim 51, wherein the incompletely pluripotent cells do not express ALP-1 and the more fully pluripotent cells express ALP-1.
57. 52. The method of claim 51, wherein the epigenetic modifier is valproic acid or parnate.
